

# EVER 2007

---

## Programme book




10<sup>th</sup>  
anniversary  
congress



October 3-6, 2007  
Portoroz, Slovenia

21 CME credits

[www.ever.be](http://www.ever.be)



BE IN A POSITION  
TO SUCCEED.

DUOTRAV™ Solution, combining two powerful agents into a single bottle, decreases IOP by up to 38% (12mmHg) from baseline<sup>1</sup>. DUOTRAV™ Solution's convenient once-a-day dosing, either morning or evening, enhances patient compliance.  
BE IN A POSITION TO SUCCEED in the management of glaucoma.

**DUOTRAV**™ ▼  
40 micrograms/ml + 5 mg/ml eye drops solution (travoprost/timolol)

**Reference:** 1. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1-7. ©2006 Alcon, Inc.

Consult the Summary of Product Characteristics before prescribing, particularly in relation to side-effects, precautions and contraindications.

DuoTrav™ (travoprost and timolol maleate). **Presentation** Plastic bottle containing 2.5ml eye drops. Each 1 ml contains 40 micrograms of travoprost, 5 mg of timolol (as timolol maleate), benzalkonium chloride 0.15 mg, and polyoxyethylene hydrogenated castor oil 40 (HCO-40) 5 mg. **Indication** Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. **Usage/Administration** Adults, including the elderly One drop into affected eye(s) once daily, morning or evening. Administer at same time each day. **Paediatric patients** Not recommended. **Use in hepatic and renal impairment** No studies conducted with DuoTrav. **Contraindications** Hypersensitivity to any component of product. Bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. Severe allergic rhinitis, bronchial hyper reactivity; corneal dystrophies, hypersensitivity to other beta-blockers. **Warnings and precautions** **Systemic effects** Cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have pulse rates checked. Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and cardiac failure, have been reported following administration of timolol. Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) as beta-blockers may mask the signs and symptoms of acute hypoglycaemia and hyperthyroidism, and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension. **Anaphylactic reactions** While taking beta-blockers, patients with a history of atopy or

severe anaphylactic reaction to a variety of allergens may be unresponsive to usual doses of adrenaline used to treat anaphylactic reactions. **Concomitant Therapy** Timolol may interact with other products. Effect on IOP or known effects of systemic beta-blockade may be potentiated when DuoTrav is given to patients already taking oral beta-blockers. Use of two local beta-blockers or local prostaglandins is not recommended. **Ocular effects** Travoprost may increase brown pigment within the iris leading to a gradual change in eye colour. Predominantly seen in patients with mixed coloured irides, may be permanent. Unilateral treatment can result in permanent heterochromia. Eyelash changes (length, thickness, pigmentation and/or number of lashes). Long-term consequences unknown. Caution in patients with inflammatory ocular conditions, other types of glaucoma (including neovascular, angle-closure, narrow-angle, congenital, pigmentary or pseudoxfoliative glaucoma), thyroid eye disease, open-angle glaucoma of pseudophakic patients, aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, patients with known risk factors for cystoid macular oedema, or in patients with known predisposing risk factors for iritis/uveitis. **Contact lenses** Avoid use of soft contact lenses. Instruct patients to remove contact lenses prior to drop application and wait 15 minutes after instillation before reinsertion. Polyoxyethylene hydrogenated castor oil 40 may cause skin reactions. **Interactions** No interaction studies have been performed. Potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine or beta-blockers, antiarrhythmics, digitalis glycosides or parasympathomimetics. Hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers. **Women of childbearing potential** Do not use unless adequate contraceptive measures are in place. **Pregnancy** Do not use unless clearly necessary. **Lactation** Not recommended. **Driving /use of machines** Eye drop instillation may blur vision. **Undesirable effects** No serious undesirable effects related to DuoTrav were reported. Most frequently reported

treatment-related undesirable effect was ocular hyperaemia (15%). 98% of patients who experienced ocular hyperaemia did not discontinue therapy as a result. **Other very common/common undesirable effects reported in clinical trials with DuoTrav** Nervousness, dizziness, headache, eye (irritation, pain, swelling, discomfort, abnormal sensation, dryness, pruritus) punctate keratitis, anterior chamber cells and flare, photophobia, conjunctival haemorrhage, corneal staining, vision (acuity reduced, disturbance, blurred) conjunctivitis allergic, lacrimation increased, eyelid (erythema, irritation, dermatitis), asthenopia, growth of eyelashes, heart rate and blood pressure changes, bronchospasm, urticaria, skin hyperpigmentation (periorificial), pain in extremity. **Additional undesirable treatment-related effects have been reported in clinical trials with concomitant therapy (travoprost and timolol) or with monotherapy with travoprost, or postmarketing events reported in the SPC for travoprost or timolol that have not been reported with DuoTrav:** Refer to SPC for additional information and before prescribing. **Overdose** Treat symptomatically. Timolol does not dialyse readily. Incompatibilities Not applicable. **Shelf life** 3 years, discard 4 weeks after first opening. **Special precautions for storage/disposal** None. **PL Holder and Further Information** Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts HP2 7UD, United Kingdom. **PL Number** EU/1/06/338/001-003 **Date of Preparation of Prescribing Information** March 2006 **Packaging Quantities and Basic NHS and GMS price(s)** Cartons containing 1 x 2.5ml (£13.20, €19.66), 3 x 2.5ml (£37.62, €56.02), 6 x 2.5ml not marketed. **Legal Category** POM.

**Adverse events should be reported to Alcon (UK) Medical Information on 01442 341234. Information about adverse event reporting can also be found on [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk)**

**Date of preparation:** August 2006.

**DUO:EVER:0806(HC)**

**Alcon®**



## » Word from the president

Dear colleagues and friends,

It's a great pleasure to invite you to our annual meeting.

EVER continues to improve and grow. This year marks EVERs 10th year and is characterised by the most comprehensive scientific program ever offered in our history. I am pleased that we have been able to outline an excellent scientific program with almost 40 Special Interest Symposia covering a wide range of up-to-date topics. In addition, six Plenary Lectures will be delivered by international guests of EVER focusing on important progress made in basic and clinical research. Some of you may have made already plans to arrive on Wednesday to attend one of our six courses. You may notice that for the first time we have been grading them from beginner through advanced level that allows you to make an even better, individual choice.

It is becoming a tradition for EVER to host other international organisations and to organise combined sessions with ARVO, EVI, ISCEV, FRO and OOG. This not only strengthens our already excellent scientific program but also emphasises the international reputation that EVER has achieved. EVER is happy to consider similar collaboration with other societies.

Our new venue is Portoroz in Slovenia situated at the Adriatic coast. The congress center and facilities there will guarantee optimal conditions for our extended program. At the same time Portoroz provides us the relaxed atmosphere that will stimulate exchange and communication with friends and colleagues. EVER will provide a social program, including a welcome reception, cultural events and a dinner at a historical location. I am sure that these perspectives will make the EVER meeting this year a great scientific and social event!

Looking forward to welcome you in Portoroz,

*Yours Sincerely,*

*Prof. Dr. Uwe Pleyer, FEBO*



**Uwe Pleyer**

EVER President 2007

## About EVER

EVER is a non-profit organisation. The aims of the Association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is currently the leading ophthalmological research association in Europe which covers all areas of ophthalmology and visual sciences.

## Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the member's module, on [www.ever.be](http://www.ever.be) and fill in the name of an EVER member who will endorse their application. If candidates do not know a member who can endorse their application, they should write to the EVER office, who will take appropriate action. The candidate becomes a member upon recommendation by the EVER board and upon payment of the dues.

As EVER member your benefits are:

- reduced fee for the annual meeting
- possibility of organizing Special Interest Symposia (SIS) during the annual meeting
- voting rights for the election of the Board Members
- free electronic subscription to *Acta Ophthalmologica Scandinavica*, the EVER journal
- travel grants for best paper in each section

## Elections

This year, the term of Secretary General is coming to an end. Elections for a new Secretary General are open to all full members. The list of candidates is on the member's web page.

Also new representatives of the scientific sections Cornea/Ocular Surface and Glaucoma will be elected through electronic voting. The result of the elections will be announced at the General Assembly on Saturday, October 6, 2007.

The scientific sections will hold their Business Meetings on Friday, October 5, 2007 from 19:00 till 20:00. The agenda is available on page 42.

The sections on Lens and Cataract and on Retina/Vitreous will nominate candidates for the succession of their representatives in the Board of EVER for elections in 2008.

The statutes and by-laws are available on the website: [www.ever.be](http://www.ever.be) » about » statutes

## Executive Committee



*Uwe Pleyer  
President*



*Ivan Haefliger  
Vice President*



*Jost Jonas  
Secretary General*



*Pinar Aydin  
Treasurer*



*Tero Kivelä  
Past President /  
Programme Secretary*



*Harminder Dua  
President Elect*



*Jean-Jacques De Laey  
Belgian representative*



*Selim Orgul  
Vice-president Elect*

## EVER Office



*Marlene Verlaeckt  
Executive administrator*



*Bruno Van Damme  
Webmaster*



*Christy Lacroix  
Assistant*

*Kapucijnenvoer 33, 3000 Leuven, Belgium  
marlene.verlaeckt@ever.be  
www.ever.be*

## BOARD Members

### Section Chairs



Erich Knop  
Anatomy /  
Cell biology



Harminder Dua  
Cornea /  
Ocular Surface



Selim Orgul  
Glaucoma



Carl Herbort  
Immunology /  
Microbiology



Marcella Votruba  
Molecular Biology /  
Genetics / Epidem.



Lene Martin  
Neuro-ophth. / Strabism. /  
Paediatric / History



Charlotta All-Ericsson  
Pathology / Oncology



Ralph Michael  
Lens / Cataract



Graham Holder  
Vision Sciences / Electrophysiol. /  
Physiol. optic



Leopold Schmetterer  
Physiology / Biochem. /  
Pharmacology



Charles Riva  
Retina / Vitreous

### Regional representatives



Francesco Bandello  
Italy



Gabor Hollo  
East Europe



Pinar Aydin  
Greece, Balkan, Middle-East

### Co-opted



Per Söderberg  
EVER-Acta



Amanda Churchill  
Advisor

### Local representative



Marko Hawlina  
Slovenia

## Location

EVER 2007 will be held at the Bernardin Convention Center in Portoroz, Slovenia (visit the website on [www.h-bernardin.si](http://www.h-bernardin.si)).

The scientific programme starts on Wednesday, October 3 at 14:00 and concludes on Saturday, October 6 at 19:00.

## Registration

Everyone attending the scientific sessions—whether or not an EVER member, invited speaker, accompanying person or presenter—must register and pay the registration fee.

The early registration deadline is September 1, 2007. At any time, you can register and pay your registration fee on-line at [www.ever.be](http://www.ever.be). On-site registration will be open from Wednesday on October 3, 12:00.

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- registering as an accompanying person entitles you to attend the EVER social events, but not the scientific programme
- refunds – up to 75% of the registration fee – will be granted for any cancellation received in writing, prior to September 20, 2007. Refunds will not be granted for later cancellation or no-shows.

## Registration fees (in EUR) after Sept. 1, 2007

EVER member	350	275 *
SIS-invited speaker	350	275 *
Member-in-training	175	140 *
Non-member	570	460 *
Non-member-in-training	280	220 *
Course	50	30 *
Accompanying person	115	115 *

\* Only for citizens of listed countries: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Congo, Croatia, Czech Republic, Egypt, Estonia, Georgia, Hungary, India, North Korea, Latvia, Libya, Lithuania, Macedonia, Moldova, Morocco, Poland, Romania, Russia, Serbia and Montenegro, Slovakia, Slovenia, Tunisia, Turkey, Ukraine

The list of countries will be updated annually and is based on the membership roster.

## Website

The EVER website [www.ever.be](http://www.ever.be) has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2007 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- go to useful links
- express your vote for officers
- print your CME certificate after the congress



## Travel

Portoroz can be reached from Trieste airport and from Ljubljana airport.

A congress shuttle service is available. Please book in advance through [www.ever.be](http://www.ever.be) » housing and transfer.

- Congress Transfer Service\* from Ljubljana and Trieste airport to Portoroz: on arrival dates October 2 and October 3.
- On departure dates October 6 and October 7.
- One-way shuttle bus transfer:  
Ljubljana airport - Portoroz: 25 EUR per person,  
Trieste airport - Portoroz: 20 EUR per person.
- Private transfer: individual service, private car or van transfer with English-speaking driver can be organised. Please contact the technical organiser for more details at [housing@cd-cc.si](mailto:housing@cd-cc.si).

\* *Arrivals: The congress transfer service reserves the right to combine transfers for participants of the EVER congress with a maximum waiting time of 1 hour  
Departures: Please reconfirm your departure transfer at least 48 hrs prior to your departure at the housing desk.*

## Tourist information

Slovenia is a country where the Alps meet the sea, a country of geographical diversity and natural beauty that you will be able to observe already on the way from Ljubljana airport to the town of Portoroz. Portoroz and Piran are two towns next to each other. The old tradition of Piran is matched with modern amenities in hotels that offer relaxing atmosphere and splendour.

The congress center is situated right in the middle of the two. The towns have many places offering pleasant atmosphere, with seafood restaurants and delicious wines.



## Weather

October is an excellent time to visit Slovenia. It is the latter part of the warmest and driest time of the year.

## Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.

## Social programme

The social programme is open for all participants and registered accompanying persons:

- Wednesday 19:00, the EVER Welcome reception
- Saturday 20:00, the Congress dinner

## Coffee

Coffee and soft drinks are provided throughout the meeting from 09:30 until 11:00 and from 15:30 until 17:30 and are included in the registration fee.

## Internet access

Wi-Fi internet access will be provided in room Europa C.

## Scientific programme access

You can visit [www.ever.be](http://www.ever.be) for the most up-to-date scientific programme.

The abstracts will be published on-line in a special issue of Acta Ophthalmologica Scandinavica.



## TFOS awards 2007






We are pleased to announce that the following three researchers have received a travel award from the Tear Film and Ocular Surface Society for the three best abstracts submitted to EVER 2007 by young researchers in the cornea section:

- **María Fideliz DE LA PAZ, Barcelona, Spain**  
Wedge resection for high astigmatism in penetrating keratoplasty for keratoconus: refractive and histopathologic changes
- **Laurent BATAILLE, Alicante, Spain**  
Influence of platelets on the healing of dry eye of patients treated with topical eye drops of autologous Platelet-Rich Plasma (PRP)
- **Pier Luigi DODI, Parma, Italy**  
NGF topical administration in dogs affected by spontaneous keratoconjunctivitis sicca

## Business meetings

- European Vision Institute, EVI  
General Assembly, Friday, 16:00-18:00, in room Nautilus
- EVER business meetings of the scientific sections  
Friday, 19:00-20:00  
COS / ACB, in room Europa A  
RV / IM, in room Europa B  
G / MBGE, in room Emerald I  
LC / NSPH, in room Emerald II  
PPB / VEP, in room Mediteranea I  
PO, in room Adria
- European Board of Ophthalmology, EBO  
Saturday, 12:50-15:30, in room VIP
- Ophthalmic Oncology Group, OOG  
Saturday, 16:30-18:00, in room Adria



## Photographs



It is strictly forbidden to take photographs or videos of the presentations in the lecture rooms.

## Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2007.

## No shows

Please note that any first author, whose paper or poster, once it has been accepted, is not presented without a valid excuse, will be prohibited from presenting papers at EVER for the next two years.

## Guidelines for speakers: handling presentations at EVER 2007

EVER 2007 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:

The supported software for presentation is PowerPoint

Oral presentations in the free paper sessions are limited to eight minutes, followed by four minutes of discussion. The session chairman will strictly enforce this schedule.

Rapid fire presentations should last no longer than 3-4 minutes with a 2 further minutes for questions from the audience. Do not use more than 2-3 PowerPoint slides for this presentations.

In the Speaker's room Mediteranea II, a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied.

Inside each presentation room, a technical assistant starts each presentation at the right time using one of the fixed computers connected to the central congress network.

We do not allow the use of personal laptops for presentations except in rare circumstances\*. If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed. Of course, the easiest

\* In rare circumstances, the technician will allow the use of personal laptops. For example, when the presentation has been created with Corel, Apple Keynote or movie creating software.

way is to bring your presentation on CD, DVD or memory stick. E-mailing or uploading of presentations will not be encouraged but can be used in special circumstances.

When a speaker wants to modify the presentation after it has been transferred to the central congress network, it can of course be updated to the new version upon request.

At the end of the congress, all presentations will be deleted so no copyright issues will arise.

## Guidelines for posters

The poster exhibition takes place in Room Europa C. Posters must be brought to the congress by the presenting author and should not be mailed in advance. The required dimensions are 95 cm (width) by 180 cm (height). NOTE: Portrait shape.

Each poster is exhibited for one day only. You should install your poster in the morning before 9:00 and remove it the same day after 19:00. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sessions of this programme book.

You should ensure that you are standing beside your poster during the poster session. On Thursday and Friday from 16:30 to 17:25, on Saturday from 15:35 to 16:25. During this time, moderators will be voting which poster should win the poster prize.

Some authors of posters, selected by the programme committee will be invited to give a brief *rapid fire* oral presentation.

## Poster prizes

A poster prize of 100 EUR will be awarded for the best poster in each section. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday, 6 October.




## EVER travel grants

We are pleased to announce that the following 11 members have received a travel grant of 400 EUR each from the EVER Sections:


- Anatomy/Cell Biology:  
Kati-Sisko VELLONEN, Helsinki, Finland
- Cornea / Ocular Surface:  
Gilles THURET, Saint-Etienne, France
- Glaucoma:  
Raquel FERNANDEZ DURANGO, Madrid, Spain
- Immunology/Microbiology:  
Valerie TOUITOU, Paris, France
- Lens and Cataract:  
Sally CHE, Auckland, New Zealand
- Molecular Biology/Genetics/Epidemiology:  
Oliver PUK, Neuherberg, Germany
- Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History:  
Lajos Rudolf KOZAK, Budapest, Hungary
- Pathology/Oncology:  
Bruno FERNANDES, Montreal, Canada
- Physiology/Biochemistry/Pharmacology:  
Simon BACKHOUSE, Auckland, New Zealand
- Retina/Vitreous:  
Irmela MANTEL, Lausanne, Switzerland
- Vision Sciences/Electrophysiol./Physiol. Optic:  
Marika WAHLBERG, Hägersten, Sweden



10<sup>th</sup>  
anniversary congress



WEDNESDAY  
3 October  
07



<b>Europa A</b>	<b>Course 1: Amniotic membrane in ophthalmology: Applications and limitations</b>		14:00 – 16:45																								
Course	Harminder S DUA, Jean-Jacques GICQUEL																										
<p>The amniotic membrane has been prolifically used in ophthalmology for almost two decades. With cumulative clinical experience and continued scientific analysis of the membrane clear benefits and limitations of the membrane are now established. The major advantage is that in some clinical indications it offers a management option where none existed and the clear disadvantage is that the membrane is far from standardised resulting in variable, often unsuccessful outcomes. This is borne out by extensive biochemical and proteomic studies. This course will aim to start from basics and cover history, clinical indications, applications and limitations of the membrane with video illustrations. Results of scientific studies and their clinical implications will be discussed. Current attempts to standardise the membrane or generate a consistent synthetic membrane will be introduced.</p> <p>The attendee should be able to leave better informed and with a better understanding of the scientific basis of the proposed mechanisms of action; clinical including surgical tips on the use of the membrane; what to expect in different indications and how to evaluate outcomes.</p> <p>All speakers have extensive clinical and research experience on the handling and use of the membrane.</p>																											
<table> <tbody> <tr> <td>14:00</td><td>1311</td><td>Amniotic Membrane Transplantation (AMT): Historical overview DUA HS–Nottingham</td><td></td></tr> <tr> <td>14:05</td><td>1312</td><td>Clinical applications and benefits of amniotic membrane MAHARAJAN S–Nottingham</td><td></td></tr> <tr> <td>14:20</td><td>1313</td><td>Amniotic Membrane Transplant (AMT): Evaluation of Outcomes DUA HS, HOPKINSON A–Nottingham</td><td></td></tr> <tr> <td>14:35</td><td>1314</td><td>Limitations of the amniotic membrane HOPKINSON A–Nottingham</td><td></td></tr> <tr> <td>14:50</td><td></td><td>Surgical Videos: tips and techniques</td><td></td></tr> <tr> <td>15:15</td><td>1315</td><td>Future Directions: Standardised membranes and synthetic membranes GICQUEL JJ–Poitiers</td><td></td></tr> </tbody> </table>				14:00	1311	Amniotic Membrane Transplantation (AMT): Historical overview DUA HS–Nottingham		14:05	1312	Clinical applications and benefits of amniotic membrane MAHARAJAN S–Nottingham		14:20	1313	Amniotic Membrane Transplant (AMT): Evaluation of Outcomes DUA HS, HOPKINSON A–Nottingham		14:35	1314	Limitations of the amniotic membrane HOPKINSON A–Nottingham		14:50		Surgical Videos: tips and techniques		15:15	1315	Future Directions: Standardised membranes and synthetic membranes GICQUEL JJ–Poitiers	
14:00	1311	Amniotic Membrane Transplantation (AMT): Historical overview DUA HS–Nottingham																									
14:05	1312	Clinical applications and benefits of amniotic membrane MAHARAJAN S–Nottingham																									
14:20	1313	Amniotic Membrane Transplant (AMT): Evaluation of Outcomes DUA HS, HOPKINSON A–Nottingham																									
14:35	1314	Limitations of the amniotic membrane HOPKINSON A–Nottingham																									
14:50		Surgical Videos: tips and techniques																									
15:15	1315	Future Directions: Standardised membranes and synthetic membranes GICQUEL JJ–Poitiers																									
<b>Europa B</b>	<b>Course 2: Corneal infectious diseases</b>		14:00 – 16:45																								
Course	Jean-Jacques GICQUEL, Tristan BOURCIER																										
<p>Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keroplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections.</p>																											
<table> <tbody> <tr> <td>14:00</td><td>1321</td><td>Bacterial keratitis BOURCIER T–Strasbourg</td><td></td></tr> <tr> <td>14:30</td><td>1322</td><td>Parasitic infection KODJIKIAN L–Lyon</td><td></td></tr> <tr> <td>15:00</td><td>1323</td><td>Corneal fungal infections: practical diagnosis and treatment GICQUEL JJ–Poitiers</td><td></td></tr> </tbody> </table>				14:00	1321	Bacterial keratitis BOURCIER T–Strasbourg		14:30	1322	Parasitic infection KODJIKIAN L–Lyon		15:00	1323	Corneal fungal infections: practical diagnosis and treatment GICQUEL JJ–Poitiers													
14:00	1321	Bacterial keratitis BOURCIER T–Strasbourg																									
14:30	1322	Parasitic infection KODJIKIAN L–Lyon																									
15:00	1323	Corneal fungal infections: practical diagnosis and treatment GICQUEL JJ–Poitiers																									
<b>Emerald I</b>	<b>Course 3: Pediatric ophthalmology examination</b>		14:00 – 16:45																								
Course	Lene MARTIN, Pinar AYDIN																										
<p>Ophthalmological examination of pediatric patients requires special techniques and skills. This course is aiming to teach practical information and skills in:</p> <ol style="list-style-type: none"> <li>1. Examining children with multiple handicaps</li> <li>2. Measuring and evaluating binocular vision</li> <li>3. Measuring vision in children</li> <li>4. Assessing eye movements</li> </ol>																											
<table> <tbody> <tr> <td>14:00</td><td>1331</td><td>Measuring vision in children MARTIN L–Stockholm</td><td></td></tr> <tr> <td>14:25</td><td>1332</td><td>Examining children with multiple handicaps ARING E–Göteborg</td><td></td></tr> <tr> <td>14:50</td><td>1333</td><td>Measuring and evaluating binocular vision BRAUTASET R–Stockholm</td><td></td></tr> <tr> <td>15:15</td><td>1334</td><td>Assessing eye movements BERK T–Izmir</td><td></td></tr> </tbody> </table>				14:00	1331	Measuring vision in children MARTIN L–Stockholm		14:25	1332	Examining children with multiple handicaps ARING E–Göteborg		14:50	1333	Measuring and evaluating binocular vision BRAUTASET R–Stockholm		15:15	1334	Assessing eye movements BERK T–Izmir									
14:00	1331	Measuring vision in children MARTIN L–Stockholm																									
14:25	1332	Examining children with multiple handicaps ARING E–Göteborg																									
14:50	1333	Measuring and evaluating binocular vision BRAUTASET R–Stockholm																									
15:15	1334	Assessing eye movements BERK T–Izmir																									



<b>Emerald II</b>	<b>Course 4: Introduction in statistics</b>	14:00 – 16:45
Course	Daniel MOJON, Stefania MOJON - AZZI	
During this course the basic principles of statistics relevant to biomedical research will be transmitted in an interactive way. The following topics will be covered: design of experiments, sampling, scales of measurement, descriptive statistics, parametric and non-parametric tests, one-sided and two-sided tests, paired and unpaired tests, regression and correlation, confidence intervals, multiple comparisons, power of tests, and bias.		

<b>Mediterranea I</b>	<b>Course 5: Diagnosis and management of endophthalmitis</b>	14:00 – 16:45
Course	Marc D DE SMET, Laurent KODJIKIAN	
The endophthalmitis course is meant to cover current concepts on the epidemiology, pathophysiology and management of common causes of endophthalmitis. The participant will be able to place the Endophthalmitis Vitrectomy Study in a proper context 15 years after its completion. He/she should be capable of recognizing tell-tale signs of endophthalmitis and choose an appropriate course of action, including the choice, mode of delivery, and frequency of administration of antibiotics. Also discussed will be the role and need for PCR and culture in establishing a diagnosis, and the timing and need for surgical intervention / debridement of the intraocular space. Plenty of time will be devoted to discussion of cases and therapeutic approaches with a faculty composed of leading European experts.		
14:00	1351	Endophthalmitis epidemiology - types of bacteria involved, their frequency, settings where it occurs (lens types etc) KODJIKIAN L–Lyon
14:15	1352	Preventative measures - wound design in cataract surgery, wound integrity and the use of intracameral antibiotics MONTAN P–Stockholm
14:30	1353	Diagnosis - when to suspect, what to do, how and when, what to expect from the microbiology lab. The role of PCR in the diagnosis BODAGHI B–Paris
14:45	1354	Choice of antibiotics and how long to treat COCHEREAU IC–Angers
15:00	1355	Surgical management of endophthalmitis standard post-op cases EVS or post EVS DE SMET M–Antwerp
15:15	1356	Surgical management of specific cases post traumatic / bleb / intravitreal injection ABU EL ASRAR A–Riyadh

<b>Adria</b>	<b>Course 6: Ophthalmologic pathology: Basics, updates and new insights</b>	14:00 – 16:45
Course	Sarah COUPLAND, Karin LOEFFLER	
The aim of this course is to provide a basic overview of ophthalmic pathology, its continuing role in modern ophthalmology, and to provide practical guidelines for the evaluation of ocular specimens of varying types (e.g. diagnostic vitrectomies, conjunctival, orbital and chororetinal biopsies, enucleated eyes as well as exenteration specimens). Furthermore, the course will cover newer technologies and methodologies in diagnostics, such as polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH) as well as gene expression profiling, and how these can be incorporated into the diagnostic panel in ophthalmic pathology. This course will be based on examples from real life and will be given from a practical rather than theoretical point of view. It is aimed at ophthalmologists with an interest in pathology, as well as at pathologists and basic researchers specialising in ocular pathology.		

<b>Daphnia</b>	<b>Course 7: European Board of Ophthalmology (EBO) exam course</b>	14:00 – 16:45
Course	Bahram BODAGHI, Marc D. DE SMET, Carl P. HERBORT, Piergiorgio NERI, Carlos E. PAVESIO, Uwe PLEYER	
Refreshment course on UVEITIS for the preparation of the EBO examination ( <a href="http://www.ebo-online.org/eboed">www.ebo-online.org/eboed</a> ).		
The aim of this course is the review five major topics of intraocular inflammation and infections. A pre-test composed of multiple choice questions will evaluate the basic knowledge of the participants initially. The test will be followed by quiz and case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be basic and aimed at pathologies that are frequent. A post-test will be provided in order to evaluate the acquisition of knowledge.		

## Opening Ceremony



**Welcome**  
17:00 – 17:15  
**Europa A**

**Welcome by the President EVER 2007**

Uwe PLEYER — President



**AER Lecture**  
17:20 – 18:00  
**Europa A**

**On considerations of the corneal thickness**

Niels EHLERS, Arhus - Denmark  
Introduction by Anthony BRON



**European Ophthalmic Heritage**  
18:05 – 18:20  
**Europa A**

**From Helmholtz to the scanning laser ophthalmoscope  
150 years ophthalmoscopy**

Jean-Jacques DE LAEY, Ghent - Belgium  
Introduction of the series by Tero KIVELÄ



**EVER Lecture**  
18:25 – 19:00  
**Europa A**

**Can uveal melanoma be conquered?**

Tero KIVELÄ, Helsinki - Finland  
Introduction by Uwe PLEYER



**Social**  
19:00-19:30  
**Europa A**

**Opening concert**


Zoran Predin, acoustic guitar  
Anja Bukovec, violin  
Zoran Skrinjar, piano




**Social**  
19:30-21:00

**EVER Welcome reception**

On the St. Bernardin terrace



10<sup>th</sup>  
anniversary congress



EVER  
*Thursday*  
4 October  
07

<b>Europa A</b>	<b>Ocular zoonosis and uveitis</b>		08:30 – 10:00
SIS	Laurent KODJIKIAN, Marc D DE SMET		



08:30	2111	Lyme disease (Borreliosis) BOURCIER T–Strasbourg
08:42	2112	Bartonellosis GARWEG JG–Bern
08:54	2113	Toxocariasis HERBORT C–Lausanne
09:06	2114	Leptospirosis LIESENFELD O–Berlin
09:18	2115	Brucellosis DE SMET M–Antwerp
09:30	2116	Ocular toxoplasmosis KODJIKIAN L–Lyon
09:42	2117	Prion disease BODAGHI B–Paris

<b>Europa B</b>	<b>Free Papers: Epidemiology and genetics</b>		08:30 – 10:00
FP	Jeremy GUGGENHEIM, Teodosio LIBONDI		

08:30	2121	Age-related cataracts in a German population-based study (KORA S4) GRAW J, KLOPP N, ILLIG T, GIEGER C, WELZL G, LÖWEL H, ZAHLMANN G, HOLLE R, WICHMANN HE–Neuherberg
08:42	2122	The ocular and systemic factors associated with diabetes mellitus in the Beijing eye study LIBONDI T, XU L, XIE X, WANG Y, JONAS JB–Naples, Beijing, Mannheim
08:54	2123	Genotype–phenotype correlation in AMD: The influence of complement factor H polymorphism MANTEL I, DROZ I, AMBRESIN A, SCHORDERET D, MUNIER F–Lausanne, Sion
09:06	2124	Genetic markers for proliferative diabetic retinopathy in type 2 diabetes GLOBOCNIK PETROVIC M, HAWLINA M, PETERLIN BORUT, PETROVIC D–Ljubljana
09:18	2125	Congenital aniridia POPPER M, BAUSZ M, TURI E, SENYI K, KNEZY K, SUVEGES I–Budapest
09:30	2126 <i>rf</i>	Clinical management of congenital achromatopsia PINELLO L, MAZZAROLO M, MAIMONE PE, SUPPIEJ A, CALDIRONI P–Padua
09:36	2127 <i>rf</i>	Family with Brittle Cornea Syndrome TOSOUNIDIS IH, MCKEAG D, AU L, AUTALLAH S, BLACK G, BONSHEK RE–Manchester

<b>Emerald I</b>	<b>Adherence with medical therapy</b>		08:30 – 10:00
SIS	Anastasios G.P. KONSTAS		



08:30	2131	The problem of non-adherence with medical therapy GEORGIADOU I–Thessaloniki
08:45	2132	Adherence with antiglaucoma therapy CARASSA RG–Milano
09:00	2133	Patient reported problems and adherence to glaucoma medications in the United States and India SLEATH B–Chapel Hill (North Carolina)
09:15	2134	Fixed combinations and adherence HOLLO G–Budapest
09:30	2135	Objective evaluation of adjunctive glaucoma therapy ROBIN A–Baltimore
09:45	2136	Update on a new randomised adherence study TSIRONI S–Thessaloniki

<b>Emerald II</b>	<b>Doctor, I don't like bright lights</b>	08:30 – 10:00
SIS	Graham HOLDER, Bart LEROY	

08:30	2141	The first consultation & photophobia in anterior segment disease HAWLINA M–Ljubljana
08:52	2142	Photophobia in ocular developmental disease MOORE T–London
09:14	2143	Photophobia in inherited retinal disease LEROY BP–Ghent
09:36	2144	The role of electrophysiology HOLDER GE–London

<b>Mediteranea I</b>	<b>Psycho - neuro - immunology and the eye</b>	08:30 – 10:00
SIS	Johannes NEPP, Nadja KNOP, Erich KNOP	

08:30	2151	Functional anatomy, innervation and immune regulation of the ocular surface KNOP N, KNOP E–Hannover, Berlin
08:48	2152	Principles of psycho-immunological relations – Do they apply to the eye? NEPP J–Vienna
09:06	2153	Psychosomatics and implications on clinics of patients with blepharospasm RICHTER MÜKSCH S, NEPP J, FUNK M–Vienna
09:24	2154	Influence of bone marrow transplantation on the eye and psychopathology KOUBA M, NEPP J, BERGER P, GREINIX H, KALHS P, FUNK M, MITTERBAUER M–Vienna
09:42	2155	The eyes – Doors to the world ECKER B, GERBER G, REINELT T–Vienna

<b>Adria</b>	<b>FRO: Belgian Fund for Research in Ophthalmology 1</b>	08:30 – 10:00
Joint M.	Marie - José TASSIGNON	



08:30	2161	Topical cyclosporine in the treatment of vernal keratoconjunctivitis in a Rwandan eye clinic: a prospective, randomized, double-masked, clinical trial DE SMEDT S–Gent
08:45		Discussion
08:50	2162	Structural and functional arterial properties in low-tension glaucoma HEIREMAN S–Gent
09:05		Discussion
09:10	2163	Correlation between visual field defects and fitness to drive in glaucoma patients LELOUP E–Gent
09:25		Discussion
09:30	2164	Serum markers in screening for regional and distant metastases in conjunctival melanoma patients MISSOTTEN G–Antwerpen
09:45		Discussion

<b>Keynote Lecture</b> 10:15 – 10:55 <b>Europa A</b>	<b>Delivery of eye care in developing countries - Role of research</b> Gullapali RAO, Hyderabad - India Introduction by Jost JONAS
--	--



<b>Europa A</b>	<b>Free Papers: Immunology / Microbiology</b>		11:15 – 12:45
FP	Carl P HERBORT, Uwe PLEYER		
11:15	2211	Microbiological culture and universal PCR yield after intravitreal injection of antibiotics in acute endophthalmitis following cataract surgery VINH V, PALOMBI K, CREUZOT-GARCHER C, BRON AM, CORNU PL, THURET G, ROMANET JP, BENITO Y, VANDENESCH F, CHIQUET C–Grenoble, Dijon, Lyon, Saint Etienne	
11:27	2212	Impaired cytokine production of tumor infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma TOUITOU V, BODAGHI B, DE KOZAK Y, CAMELO S, LEHOANG P, FRIDMAN C, FISSON S–Paris	
11:39	2213	The antilymphangiogenic effect of aqueous humour BOCK FB, ONDERKA JO, DIETRICH TD, BACHMANN BB, HOS DH, CURSIEFEN CC–Erlangen	
11:51	2214	Lymphocyte activation marker analysis in patients with sight threatening uveitis WILLERMAIN F, VEREERTBRUGGHEN H, SERVAIS G, BRUYNS C, CASPERS L, DUCHATEAU J–Bruxelles	
12:03	2215	The Uveitis subtype associated with Spondylarthropathies varies regarding to gender and the type of Spondylarthropathy involved MACKENSEN F, BECKER MD, MAX R–Heidelberg	
12:15	2216	rf Epidemiology of severe uveitis in France: a prospective multicentre study BODAGHI B, SANCHEZ-POTON A–Paris, Castries	
12:21	2217	rf Intermedial uveitis: clinical course in ten years follow up VIDOVIC VALENTINCIC N, KRAUT A, HAWLINA M, STUNF S, ROTHAVA A–Ljubljana, Utrecht	
<b>Europa B</b>	<b>Genetics of non-mendelian complex eye diseases</b>		11:15 – 12:45
SIS	Seang Mei SAW, Eric YAP		
11:15	2221	Genes and gene-environmental interactions for retinal diseases LIEW G–Sydney	
11:33	2222	Genetics of corneal endothelial dystropies VITHANI EN–Singapore	
11:51	2223	The genetics of refractive errors YAP E–Singapore	
12:09	2224	Familial correlations and gene-environment interactions for myopia SAW SM–Singapore	
12:27	2225	Myopia genetics: lessons from other complex diseases GUGGENHEIM JA–Cardiff	
<b>Emerald I</b>	<b>EURETINA: How does the laser work? The mechanism of retinal photocoagulation</b>		11:15 – 12:45
Joint M.	Einar STEFANSSON		
			
11:15	2231	Retinal photocoagulation: clinical aspects BEK T–Aarhus	
11:35	2232	The effect of laser on retinal oxygenation (animal studies) POURNARAS CJ–Genève	
11:55	2233	Retinal oximetry in humans: effect of laser HARDARSON SH–Reykjavik	
12:15	2234	Physiological effects of vitrectomy and retinal laser treatment explain their clinical effects: Vitrectomy and laser treatment both affect retinal oxygenation and benefit ischemic retinopathies STEFANSSON E–Reykjavik	
12:35		Panel discussion	

<b>Emerald II</b>	<b>Free Papers: Vision Sciences / Electrophysiol. / Physiol. Optic</b>		11:15 – 12:45
FP	Graham HOLDER, Bart LEROY		
11:15	2241	Optimal stimulus size maps in the primary visual cortex revealed by optical imaging in cats CASANOVA C, VANNI M, VILLENEUVE MY–Montreal	
11:27	2242	Mathematical analysis of the cone ERG photopic hill: Clinical applications LACHAPELLE P, GARON M, JAUFFRET C, RUFANGE M, HAMILTON R, MCCULLOCH C, KOENEKOOP RK, POLOMENO RC, LITTLE JM–Montréal, Glasgow	
11:39	2243	Improvement of S-cone mediated visual fields and rod function after correction of vitamin A deficiency HAYASHI T, TAKEUCHI T, GEKKA T, KUBO A, NAKANO T, TSUNEOKA H–Tokyo	
11:51	2244	Optical inhibition of axial myopia progression PHILLIPS JR, ANSTICE NS–Auckland	
12:03	2245	Macular abnormalities and the Rarebit Fovea Test MARTIN L, NILSSON M, WANGER P–Stockholm	
12:15	2246 rf	Fixation stability during the Rarebit Fovea Test NILSSON M, GRANATH H, WAHLBERG M, WANGER P, BRAUTASET R–Stockholm, Linköping	
<b>Mediteranea I</b>	<b>Ocular movements: structural, functional and clinical aspects</b>		11:15 – 12:45
SIS	Fatima PEDROSA DOMELLOF, Richard BRUENECH		
11:15	2251	The dynamic cell biology of extraocular muscles MCLOON L–Minneapolis	
11:33	2252	Morphological variations found in human extraocular muscles and their functional implications BRUENECH JR, KJELLEVOLD HAUGEN IB–Kongsberg	
11:51	2253	The potential role of sensory receptors in ocular movements HAUGEN IBK, BRUENECH JR–Kongsberg	
12:09	2254	Orbicularis oculi muscle and eyelid movements in health and disease VAN DER WERF F–Rotterdam	
12:27	2255	Neuromuscular junctions of human extraocular muscles: looking for new tools for medical treatment of strabismus PEDROSA DOMELLOF F, LIU JX, WILLISON HJ–Umeå, Glasgow	
<b>Adria</b>	<b>FRO: Belgian Fund for Research in Ophthalmology 2</b>		11:15 – 12:45
Joint M.	Marie - José TASSIGNON		
			
11:15	2261	Overcoming the barrier of the neural retina for the delivery of non-viral gene complexes to the retinal pigment epithelium PEETERS L–Gent	
11:30		Discussion	
11:35	2262	Role of VEGF-isoforms in pathological angiogenesis VAN BERGEN T–Leuven	
11:50		Discussion	
11:55	2263	The role of the VEGF family in anti-angiogenesis and neurodegeneration in the retina VAN DE VEIRE S–Leuven	
12:10		Discussion	
12:15	2264	Ex vivo expansion of human limbal epithelial stem cells for the treatment of corneal diseases with limbal stem cell deficiency ZAKARIA N–Antwerpen	
12:30		Discussion	

<b>Europa A</b>	<b>A Report from the International Dry Eye Workshop (DEWS)</b>		14:00 – 15:30
SIS	Debra A. SCHAUMBERG, David A. SULLIVAN		



14:00		Introduction by the moderators	
14:12	2311	Definition & classification of dry eye BRON AJ–Oxford	
14:25	2312	The epidemiology of dry eye disease SMITH JA–Bethesda, MD	
14:38	2313	Diagnostic methodology TOMLINSON A–Glasgow	
14:51	2314	Clinical trial methodology in dry eye disease SCHAUMBERG D–Boston	
15:04	2315	Management & therapy LEMP MA–Washington DC	
15:17	2316	Report on research in dry eye GIPSON IK–Boston, MA	

<b>Europa B</b>	<b>ARVO session: Mentoring: How, what, why and when</b>	14:00 – 15:30
Joint M.	Sally ATHERTON, Nicholas DELAMERE, Teodosio LIBONDI	



Who do you turn to for guidance? In the context of academic training as well as career development, the benefits of mentoring are clear. Successful individuals almost always have an informal network of colleagues they can turn to for help. Persons at the beginning of their career, when mentoring might be crucial, often have to fend for themselves. Here we will discuss the benefits of having a mentor. The speakers will give advice on how to find a mentor. There will also be talk about the rewards that come from being a mentor. Recognizing the need for mentorship, many academic institutions have established formal mentoring programs. The speakers will describe some of the elements of a successful institutional mentoring program. The first part of the session will focus on the mentoring for students and persons undergoing postdoctoral or fellowship training. After this, the emphasis will switch to mentoring during the process of career development. The third part of the session will be given to discussion of the special needs of clinician scientists who must juggle the clinic and the lab. With today's communication opportunities a good mentor does not always need to be someone close at hand. Indeed, the very best mentor might be someone in a distant time zone. The speakers discuss ways ARVO and EVER can be used as a resource to find a mentor from among society members.

<b>Emerald I</b>	<b>Glaucomatous optic neuropathy</b>	14:00 – 15:30
SIS	Kivanc GUNGOR	

14:00	2331	An overview of the pathogenesis of glaucomatous optic neuropathy GUNGOR K–Gaziantep	
14:22	2332	Optic nerve injury models in the rat TUGLU I–Manisa	
14:44	2333	Cell death in optic neuropathy VALENZUELA EG–Illinois	
15:06	2334	Effects of primary open-angle glaucoma on the globe, cross sectional area and morphology of the optic nerve and volume of the lateral geniculate body: a longitudinal study CEZAYIRLI E, TUGLU I, GUNGOR K, VAROL T, BEKIR N–Manisa	

**ACTA Lecture**

15:45-16:25

**Europa A**
**The retinal pigment epithelium, friend or foe?**

Morten la COUR, Glostrup - Denmark  
Introduction by Einar STEFANSSON

Acta  
Ophthalmologica  
Scandinavica



<b>Emerald II</b>	<b>The nasolacrimal duct: Anatomy, diagnosis, surgery and nasolacrimal duct interventions, dacryocystoplasty - Part 1</b>	14:00 – 15:30
SIS	Zahra JAVDANI	



14:00	2341	Dissectional and endoscopic anatomy of the lacrimal duct JAVDANI Z, DENEFFE G, VERBINNEN J-Mechelen
14:15	2342	Preoperative assessment before surgery of the lacrimal pathway ELOY P, LEVECQ L-Mont Godinne, Brussels
14:30	2343	Radiologic diagnostic of the lacrimal system. Measurements of the bony lacrimal canal in a European population LACHMUND U, JAVDANI Z, PILAT Y, COOLEN C, VALAVANIS A, WILHELM K-Zurich, Bonn
14:45	2344	External dacryocystorhinostomy DUCASSE A-Paris
15:00	2345	Endoscopic endonasal dacryocystorhinostomy ELOY P-Mont Godinne
15:15	2346	Non endoscopic endonasal DCR MAVRIKAKIS I-Athens

<b>Mediterranea I Free Papers: Anatomy/Cell Biology 1</b>	14:00 – 15:30
FP	Erich KNOP, Saeed AKHTAR

14:00	2351	Antimicrobial peptides on the ocular surface in health and disease ABEDIN A, MOHAMMED I, DUA HS-Nottingham
14:12	2352	Characterization within and around the Limbal Epithelial Crypt YEUNG AM, SCHLOETZER SCHREHARDT U, KULKARNI B, HOPKINSON A, KRUSE FE, DUA HS-Nottingham, Erlangen
14:24	2353	Gene expression profile of Limbal Epithelial Stem Cell niche KULKARNI B, YEUNG A, HOPKINSON A, DUA HS-Nottingham
14:36	2354	Cytokeratin 8 and 18 expression in human corneal endothelium JIRSOVA K, MERJAVA S, NEUWIRTH A-Prague
14:48	2355	Difference of ocular injury by millimeter wave exposure with different frequency KOJIMA M, YAMASHIRO Y, SASAKI H, SASAKI K-Kahoku-gun
15:00	2356	Remodelling of collagen fibrils and proteoglycans in the zebrafish cornea during development AKHTAR S, SCHONTHALER HB, BRON AJ, DAHM R-Oxford, Zurich, Vienna
15:12	2357	Characterization of efflux proteins in human corneal epithelial cells VELLONEN KS, MANNERMAA E, TURNER H, TOROPAINEN E, URTTI A-Helsinki, Kuopio, New York

<b>Adria</b>	<b>Free Papers: Oncology / Pathology 1</b>	14:00 – 15:30
FP	Laurence DESJARDINS, Edoardo MIDENA	

14:00	2361	Predicting the prognosis of ciliochoroidal uveal melanoma by its clinical characteristics: a European ophthalmic oncology group collaborative study KIVELÄ T, KUJALA E, DESJARDINS L, DAMATO B, BECHRakis N, GRANGE JD-Helsinki, Paris, Liverpool, Berlin, Lyon
14:12	2362	Fish analysis of chromosome 3 and 6 on fine needle aspiration biopsy identifies distinct uveal melanoma subgroups PARROZZANI R, BONALDI L, RADIN PP, PILOTTO E, MIDENA E-Padova
14:24	2363	Treatment of juxtapapillary choroidal melanoma MISSOTTEN GS, NAUS NC, SCHALIJ-DELFOIS NE, LUYTEN GP-Leiden, Rotterdam
14:36	2364	Matrix metalloproteinase-2 (MMP-2) is expressed in melanoma associated spongiform scleropathy (MASS) ALYAHYA GA, KOLKO M, PRAUSE JU, HEEGAARD S-Copenhagen
14:48	2365	Spontaneous choroidal haematomas: differential diagnosis with uveal melanoma: a retrospective review of 95 cases DESJARDINS L, LUMBROSO-LEROUC L, LEVY- GABRIEL C, GERBER S, BERGES O, IBA ZISEN MT-Paris
15:00	2366	Bilateral retinoblastoma: successful conservative treatment of both eyes HADJISTILIANOU T, DEFRENCESCO S-Siena

<b>Europa A</b>	<b>Free Papers: Keratoconus and corneal grafting</b>			17:30 – 19:00
FP	Gilles THURET, Philippe KESTELYN			
17:30	2411	First experience with corneal collagen UV cross-linking treatment in keratoconus patients MIKEK K, MORELA V–Ljubljana		
17:42	2412	Wedge resection for high astigmatism in penetrating keratoplasty for keratoconus: refractive and histopathologic changes DE LA PAZ MF–Barcelona		
17:54	2413	Failure of topical Cyclosporine A 2% in patients with severe ocular rosacea after penetrating keratoplasty GICQUEL JJ, BOURGES JL, LANGMAN ME, BONNERIC JG, RENARD G, DIGHIERO PL–Poitiers, Paris		
18:06	2414	Refractive and biomechanical changes with intrastromal ring segments for keratoconus MICHAEL R, DE LA PAZ MF, RIOS A, ROMO M, SALVADOR B, DELAS B, ALVAREZ DE TOLEDO JP, BARRAQUER RI–Barcelona		
18:18	2415	Orbscan evaluation of keratoconus HERNANDEZ VERDEJO J, CANADAS SUAREZ P, MARINA C, GARCIA-GONZALEZ M, TEUS MA–Madrid		
18:30	2416	Corneal graft endothelial viability assessment using the triple labeling Hoechst/Ethidium homodimer/Calcein-AM: technical improvements using 3D microscopy THURET G, PIPARELLI A, DUBAND S, PISELLI S, MURAINA M, PELOC'H M, ACQUART S, ZHAO M, PRADES JM, GAIN PG–St-Etienne, Rouen		
18:42	2417	A software system for automatic estimation of corneal epithelial cell density in confocal microscopy RUGGERI A, GRISAN E–Padova		
<b>Europa B</b>	<b>Free Papers: Genetics and animal models</b>			17:30 – 19:00
FP	Marko HAWLINA, Jeremy GUGGENHEIM			
17:30	2421	A mutation in a novel connexin-like gene affects early lens development in the mouse PUK O, LOESTER J, GRAW J–Neuherberg		
17:42	2422	To see or not to see DALKE C, FAVOR J, PUK O, GRAW J–Neuherberg		
17:54	2423	The phenotype of retinal dystrophy in patients with CERKL mutations WILKE R, AVILA-FERNÁNDEZ A, TAPIA I, GARCIA-SANDOVAL B, CANTALAPIEDRA D, VALLESPIN E, AYUSO C–Tuebingen, Madrid		
18:06	2424	Genotype/phenotype features of the Slovenian patients with Stargardt disease: four novel mutations in ABCA4 gene and three novel complex alleles identified HAWLINA M, JARC-VIDMAR M, POPOVIC P, BRECELJ J, ALLIKMETS D, ZUPAN A, GLAVAC D–Ljubljana, New York		
18:18	2425	Mapping genomic loci related to variation in visual quantitative traits in an isolated island community of Croatia VATAVUK Z, BENČIĆ G, PETRIĆ VICKOVIC I, LACMANOVIC LONCAR V, ANDRIJEVIĆ DERK B, SKUNCA J, ZRINSKAJ O, BEDNAR I, KNEZEVIC T, POLASEK O, RUDAN I–Zagreb		
18:30	2426	Autosomal dominant recurrent erosions – from non-existing to being everywhere HAMMAR B, FAGERHOLM P–Linköping		
<b>Emerald I</b>	<b>CONCORDIA: Promoting European Education in Ophthalmology</b>			17:30 – 19:00
Joint M.	Tero KIVELÄ, Stefan SEREGARD			
17:30	2431	EBO promoting European Network Education TASSIGNON MJ–President EBO		
17:42	2432	EUPO: teaching the European residents in ophthalmology: history, 2007 and future SPIELEERS W–Secretary General EUPO		
17:54	2433	SOE and the young ophthalmologist SEREGARD S–Secretary General SOE		
18:06	2434	EVER: Research in ophthalmology and vision in Europe - Visions for the future PLEYER U–President EVER 2007		
18:18	2435	Increasing mobility in Europe with SOE and EBO grants HAWLINA M–President Elect EBO		

**Poster session 1**

16:30 – 17:25

**Europa C**

Posters on pages 28-29

**Anatomy/Cell Biology - Cornea/Ocular Surface - Immunology/Microbiology - Molecular Biology/Genetics/Epidemiology - Vision Sciences/Electrophysiol./Physiol. Optic**

Luc MISSOTTEN, Fatima PEDROSA DOMELLOF, Nadja KNOP - Jean-Jacques GICQUEL, Philippe KESTELYN - Bahram BODAGHI, Marko HAWLINA - Agnes FARKAS, Jez GUGGENHEIM - Bart LEROY, Pierre LACHAPELLE

<b>Emerald II</b>	<b>The nasolacrimal duct: Anatomy, diagnosis, surgery and nasolacrimal duct interventions, dacryocystoplasty - Part 2</b>		17:30 – 19:00
SIS	Zahra JAVDANI		 sponsored

17:30	2441	Nasolacrimalduct interventions-dacryocystoplasty (Ballooncatheter dilatation in pre-and postsaccal obstructions) WILHELM K, LACHMUND U–Bonn, Zurich
17:45	2442	Endoscopic dacryocystorhinostomy and balloon-dacryocystorhinostomy and transcanalicular DCR UNGERECHTS R–Darmstadt
18:00	2443	Combined surgery: endoscopic transcanalicular DCR and balloondilatation technique JAVDANI Z, ADAM J, MEYER R, EMMERICH KH–Mechelen, Darmstadt
18:15	2444	Overview of the lacrimal stents JAVDANI Z, VALVANIS A, SALU C, LACHMUND U, WILHELM K–Mechelen, Zurich, Antwerp, Bonn
18:30	2445	Treatment of epiphora in infants STIRN KRANJC B–Ljubljana
18:45	2446	Microsurgery of canalicular stenosis SERRA F–Antibe

<b>Mediteranea I</b>	<b>ACB: Free Papers: Anatomy/Cell Biology 2</b>	17:30 – 19:00
FP	Hannu UUSITALO, Richard BRUENECH	

17:30	2451	Oxidative stress in the trabecular meshwork – Preventive effects of Prostaglandin analogues WELGE-LUSSEN U, YU AL, KAMPIK A–München
17:42	2452	Aldose Reductase Inhibition Counteracts Diabetes-Induced Retinal Oxidative Injury, Glial Activation, and Apoptosis OBROSOVA IG, SHIN J, ALI TK, JULIUS U, EL-REMEZZY A, DREL VR–Baton Rouge, LA, Augusta, GA, Dresden
17:54	2453	Haptoglobin knockout mice exhibit morphologic changes consistent with iridocorneal dysgenesis and glaucoma VAN GINDERDEUREN R, GALICIAS-ROSAS G, VANDEVEIRE S, OP 'T HOOG B, CEUPPENS J, STALMANS I–Leuven
18:06	2454	The localisation of erythropoietin and erythropoietin-receptor in the retinas of Goto-Kakizaki rats using immunohistochemical methods DEAK G, SZABO A, SERES A, NEMETH J, SZEL A–Budapest
18:18	2455	Prevention of hypoxia/reoxygenation-, H2O2- and TGF- 2-mediated increase of alphaB-crystallin and Hsp27 by the use of antioxidants YU AL–Munich
18:30	2456 rf	Bio-available zinc in the outer segments of short wavelength cones LENGYEL I, ONWOCHEI N–London
18:36	2457 rf	Metabolic stress as a contributor to physiological opening of TRP channels in blowfly (Calliphora vicina) PEROVSEK D, ZUPANCIC G–Ljubljana
18:42	2458 rf	Persistent pupillary membrane remnants attached to the anterior lens capsule CHATZIBALIS T, KARAMPATAKIS V, NTAMPOS K, VOUTAS S–Thessaloniki

<b>Adria</b>	<b>In vivo micro-anatomy of the ocular anterior segment by confocal laser scanning microscopy</b>	17:30 – 19:00
SIS	Erich KNOP, Nadja KNOP, Oliver STACHS, Rudolf GUTHOFF	

17:30	2461	Physical principles and recent developments in in-vivo confocal microscopy STACHS O–Rostock
17:42	2462	Implications of RLSM confocal laser scanning microscopy for the investigation of ocular anatomy KNOP E, KNOP N–Berlin, Hannover
17:54	2463	Distribution of dendritic cells its role in clinical differential diagnosis ZHIVOV A–Rostock
18:06	2464	Alterations of conjunctival microanatomy in dry eye disease KRAAK R–Rostock
18:18	2465	Anatomy of ocular lymphatic tissue in confocal laser scanning microscopy KNOP N, KNOP E–Hannover, Berlin
18:30	2466	Laser scanning IVCM of the limbus NUBILE M–Chieti-Pescara
18:42	2467	The corneal module of the HRT-II: A new tool for assessing ocular inflammation LABBE A, BAUDOUIN C–Paris

## Anatomy/Cell Biology

**Moderators:**
**Luc MISSOTTEN, Fatima PEDROSA DOMELLOF, Nadja KNOP**

- 201 Characterization of efflux proteins in human corneal epithelial cells  
*rf* VELLONEN KS, MANNERMAA E, TURNER H, TOROPAINEN E, URTTI A–Helsinki, Kuopio, New York
- 202 Bio-availale zinc in the outer segments of short wavelength cones  
*rf* LENGYEL I, ONWOCHEI N–London
- 203 Metabolic stress as a contributor to physiological opening of TRP channels in blowfly (*Calliphora vicina*)  
*rf* PEROVSEK D, ZUPANCIC G–Ljubljana
- 204 Persistent pupillary membrane remnants attached to the anterior lens capsule  
*rf* CHATZIBALIS T, KARAMPATAKIS V, NTAMPOS K, VOUTAS S–Thessaloniki
- 205 Interleukin1-Induced apoptosis of keratocytes: effect of biglycan  
 KOULIKOVSKA M, SHARIPO A, FAGERHOLM P–Linköping, Riga
- 206 Role of EGFR in corneal remodelling in diabetes  
 AKHTAR SAEED, BRON AJ, YOUSIF MHM, BENTER IF, AKHTAR S–Oxford, Kuwait
- 207 Ghrelin expression in the iris and ciliary epithelium of fetal and newborn rats  
 ROCHA DE SOUSA A, MOURA RS, SARAIVA J, AMARAL M, CORREIA-PINTO J, LEITE-MOREIRA A–Porto, Braga
- 208 Crosstalk of Hsp70 molecular chaperone, lysosomes and proteasomes in macroautophagy-mediated proteolysis in human retinal pigment epithelial cells  
 RYHÄNEN T, HYTTINEN J, KOPITZ J, MANNERMAA E, UUSITALO H, SALMINEN A, KAARNIRANTA K–Kuopio, Heidelberg
- 209 Effects of UDP on ARPE cells: possible involvement of P2Y6 receptors  
 JUDICE DE MENEZES RELVAS L, BOUFFIOUX C, MARCET B, COMMUNI D, BLERO D, BRUYNS C, CASPERS L, BOEYNANS JM, WILLERMAIN F–Brussels

## Cornea/Ocular Surface

**Moderators:**
**Jean-Jacques GICQUEL, Philippe KESTELYN**

- 210 Descemet membrane endothelial keratoplasty using descemetorhexis and organ-cultured donor corneal tissue  
*rf* MURAINÉ M, GARDEA E, TOUBEAU D, BRASSEUR G–Rouen
- 211 Ultrastructure of Femtosecond Laser trephination for keratoplasty  
*rf* VOSSMERBAEUMER U, KNORZ MC, JONAS JB–Mannheim
- 212 Corneoscleral transplantation for extensive infection of the cornea  
 FRESINA M, CELLINI M, LEONETTI P, BENDO E, CAMPOS EC–Bologna
- 213 NGF topical administration in dogs affected by spontaneous keratoconjunctivitis sicca  
 DODI PL, ZANOTTI C, COSTA N, ALOE L–Parma, Forlì, Catanzaro, Rome
- 214 Aberration controll with contact lenses  
 LINDSKOOG PETTERSSON A, LUNDSTROM L, UNSBO P, JARKÖ C, ALVIN A, BRAUTASET R–Stockholm
- 215 Keratocyte repopulation in UVB-exposed thioltransferase knockout mice  
 PODSKOCHY A, ZHANG Y, HO YS, LÖFGREN S–Stockholm, Detroit
- 216 Corneo-conjunctival leukoplakia: histology and confocal microscopy  
 MALANDRINI A, FRUSCHELLI M, TRAVERSI C, MOTOLESE PA, MARTONE G, MOTOLESE E–Siena
- 217 Use of sodium hyaluronate “doughnut” in corneal glueing  
 SKINNER KC, MERRICK CD, GREGORY PTS, CHRONI FC–Hastings
- 218 Counting strategies for endothelial assessment of organ cultured corneas using image analysis: comparison of border versus center method  
 DEB-JOARDAR N, ZHAO M, THURET G, ROBERT PY, GAVET Y, ACQUART S, PEOC'H M, MAUGERY J, GAIN PG–St-Etienne, Limoges

- 219 Development of an image analysis device to measure transparency, folding and gerontoxon of organ cultured corneas  
 ZHAO M, JOUBERT J, DEB-JOARDAR N, PIPPARELLI A, ACQUART S, PEOC'H M, PRADES JM, MAUGERY J, THURET G, GAIN PG–St-Etienne
- 220 Ocular surface in dry eye patients is improved after one month therapy with Systane  
 VERSURA P, PROFAZIO V, CAMPOS E–Bologna
- 221 Changes in the  $\alpha 1 - \alpha 6$  collagen IV chains in the corneas of posterior polymorphous corneal dystrophy patients  
 MERJAVA S, LISKOVA P, JIRSOVA K–Prague
- 222 4 -PDD induces Ca<sup>2+</sup> influx in human corneal epithelial cells by activating TRPV4 channels  
 MERGLER S, PAN Z, YANG H, LIU H, TACHADO SD, ZHANG F, PLEYER U, REINACH P–Berlin, New York, Cincinnati, Beth
- 223 Reconstitution of conjunctival epithelium under the influence of mesenchymal stem cells on a rabbit model of symblepharon  
 GARDEA E, GUEUDRY J, DUCLOS C, VANNIER JP, MARIE JP, LAMACZ M, MURAINÉ M–Rouen
- 224 Repair of corneal endothelium after mechanical damage under tissue culture and hypothermic conditions  
 NEJEPINSKA J, JUKLOVA K, JIRSOVA K–Prague
- 225 Effect of mitomycin C on epithelial hyperplasia after laser-assisted subepithelial keratectomy (LASEK)  
 TEUS MA, DE BENITO-LLOPIS L, ORTEGA M, EGUREN M, FERRER B–Madrid
- 226 Strong expression of matrix metalloproteinases in the melted corneas of rheumatoid arthritis patients  
 JUKLOVA K, JIRSOVA K–Prague
- 227 Changes in corneal surface aberrations after myopic INTRALASIK and LASEK: Comparison between Technolas and Esiris  
 CANADAS SUAREZ P, ARRANZ E, GARCIA-RECIO C, VILLAFRANCA M, TEUS MA–Madrid
- 228 Visual outcome and corneal aberrometry after implantation of intracorneal ring segments (INTACS) for keratoconus  
 HERNANDEZ VERDEJO J, IBARZ M, GIL-CAZORLA R, FUENTES I, TEUS MA–Madrid
- 229 Corneal backscatter after penetrating keratoplasty  
 PATEL SV, MCLAREN JW, BOURNE WM–Rochester, Minnesota
- 230 Corneal hysteresis in patients with corneal pathologies  
 HERDENER S, PFEIFER N, LAUTEBACH S, PACHE M–Freiburg
- 231 Effect of Mitomycin-C on the conjunctival goblet cell density after lasik  
 RODRIGUEZ AE, RODRIGUEZ-PRATS JL, MEZQUIDA G, ALIO JL–Alicante
- 232 Proteomic analysis of conjunctival swab by mass spectrometry  
 MCGILLIGAN V, GRAHAM JE, MOORE JE, McMULLAN G, GRAHAM RLJ, BEIRNE RO, DOWNES SC, MOORE CBT–Coleraine

## Immunology/Microbiology

### Moderators:

Bahram BODAGHI, Marko HAWLINA

- 233 Epidemiology of severe uveitis in France: a prospective multicentre study  
*rf* BODAGHI B, SANCHEZ-POTON A–Paris, Castries
- 234 Intermedial uveitis: clinical course in ten years follow up  
*rf* VIDOVIC VALENTINCIC N, KRAUT A, HAWLINA M, STUNF S, ROTHAVA A–Ljubljana, Utrecht
- 235 The effect of post-operative antibiotics on the ocular surface bacterial flora in cataract patients  
MOORE JE, GRAHAM JE, BEIRNE RO, DOWNES SC, MOORE CBT–Coleraine
- 236 Pathogen or commensal: a PCR based study of ocular surface bacteria in normal and dry eyes  
GRAHAM JE, MOORE JE, XU J, MOORE JE, GOODALL E, DOOLEY J, DARTT DA, DOWNES S, MOORE T–Coleraine, Belfast, Boston
- 237 Incidence of endophthalmitis after cataract surgery: standard diagnosis versus molecular diagnosis  
BATAILLE L, FERRER C, RODRIGUEZ A, ABAD JL, ALIO J–Alicante, San Juan de Alicante
- 238 PCR identification of Rhizobium radiobacter in post-operative endophthalmitis  
VINH V, ROMANET JP, CREUZOT-GARCHEC C, BRON AM, GAIN P, CORNUT PL, PALOMBI K, DENIS P, THURET G, CROIZÉ J, MAURIN M, PECHINOT A, VANDENESCH F, CHIQUET C–Grenoble, Dijon, Saint Etienne, Lyon
- 239 Antimicrobial treatment of presumed ocular tuberculosis  
KOUPRIANOFF SK, CHIQUET CC, BOUILLET LB, ROMANET JPR–Grenoble
- 240 Ocular inflammation secondary to syphilis infection  
PUECH CP, CHIQUET CC, PAVESE PP, BOUILLET LB, ROMANET JPR–Grenoble
- 241 Is AZOOR an autoimmune disease?  
SEIDOVA SF, WIESCHER A, FIORE B, LANZL I, MAIER M, ZIMMERMANN P–Munich
- 242 Comamonas: a not so common agent in hydrogel contact lens wearers  
LANGMAN ME, DIGHIERO PL, GICQUEL JJ–Poitiers
- 243 Recurrent giant chalazia in hyperimmunoglobulinemia E (Job's) syndrome  
PATTERI P, SERRU A, CHESSA ML, LOI M, DORE S, PINNA A–Nuoro, Sassari

## Molecular Biology/Genetics/Epidemiology

### Moderators:

Agnes FARKAS, Jez GUGGENHEIM

- 244 Clinical management of congenital achromatopsia  
*rf* PINELLO L, MAZZAROLO M, MAIMONE PE, SUPPIEJA, CALDIRONI P–Padua
- 245 Family with Brittle Cornea Syndrome  
*rf* TOSOUNIDIS IH, MCKEAG D, AU L, AUTALIAH S, BLACK G, BONSHEK RE–Manchester
- 246 Correction of congenital ptosis using Ptose-up  
ALTAN-YAYCIOGLU R, AKOVA YA–Adana, Ankara
- 247 Proof of new collagen synthesis in lid skin after Er:YAG laser skin resurfacing with in-situ hybridization  
BELTRAM M, DRNOVSEK-OLUP B–Ljubljana
- 248 Dacyroendoscopy: feasibility and value as diagnostic tool  
WILKE M, KLAUSS V, KAMPIK A–Munich
- 249 Periorbital Er:YAG laser skin resurfacing in ablative, dual mode and smooth mode – a histological comparison  
BELTRAM M, DRNOVSEK-OLUP B–Ljubljana
- 250 Frequency of headache and associated eye conditions in Congolese patients  
KAIMBO WA KAIMBO D, MISSOTTEN L–Kinshasa, Leuven
- 251 A model of paediatric eye screening program for educators  
STOJANOVIC N, KOZEIS N, GOGAKI E–Thessaloniki
- 252 Visual acuity and use of eye care services in elderly population  
LAITINEN A, KOSKINEN S, RUDANKO SL, MARTELIN T, LAATIKAINEN L, AROMAA A–Helsinki

- 253 Retinal vein occlusion signals a significant risk of mortality in the Beijing eye study  
LIBONDI T, XING L, LIU W, WANG Y, YANG H, JONAS JB–Naples, Beijing, Mannheim

- 254 Phenotype characteristics of patients with Usher syndrome type 2  
FARKAS A, LESCH B, VARSANYI B, VA'MOS R–Budapest

- 255 Identification of a novel VMD2 mutation in Slovene family with best vitelliform dystrophy  
JARC-VIDMAR M, SLAJPAH M, POPOVIC P, GLAVAC D, HAWLINA M–Ljubljana

- 256 Gene expression changes associated with endothelial cell loss during corneal organ culture  
HILLARY MC, TAYLOR AW, CARLEY F, ZAMBRANO I–Manchester

- 257 Development of lentiviral vectors for gene therapy for Usher syndrome type 1B  
HASHIMOTO T, GROISBERG R, ZHANG XM, GIBBS D, LILLO C, AZARIAN SM, WILLIAMS DS, YANG XJ–Los Angeles, CA, La Jolla, CA

- 258 Mapping candidate genes for familial high myopia in a polish population  
RYDZANICZ MA, PODFIGURNA-MUSIELAK M, MRUGACZ M, FRAJDENBERG A, LEAL SM, BEJJANI BA, GAJECKA M–Poznan, Leszno, Bialystok, Houston, Spokane

- 259 Screening for diabetic retinopathy in a rural population with an itinerant non-mydiatic camera  
GARCHER CREUZOT C, BEYNAT J, ARNAVILLE S, CHARLES A, ASTRUC K, BRON AM–Dijon

## Vision Sciences/Electrophysiolog./Physiol. Optic

### Moderators:

Bart LEROY, Pierre LACHAPELLE

- 260 Fixation stability during the Rarebit Fovea Test

- rf* NILSSON M, GRANATH H, WAHLBERG M, WANGER P, BRAUTASET R–Stockholm, Linköping

- 261 Methodology of retinal straylight assessment  
VAN DEN BERG TJTP–Amsterdam

- 262 Which color vision test should be used in progressive cone dystrophy?  
THIADENS AAH, VAN LITH-VERHOEVEN JJC, BERNAERTS MGJ, KLAVER CCW–Rotterdam, Nijmegen

- 263 Comparison of chromatic macular ERG and multifocal ERG in diabetic macular edema  
ARAKELYAN MA, BORDEEVA YUN, RYABTSEVA AA, SHAMSHINOVA AM–Moscow

- 264 Functional characterisation of rats visual system following ocular ischemia by evoked potentials and retrograde transportation of retinal ganglion cells  
JEHLE T, WINGERT K, DIMITRIU C, MESCHEDE W, LASKEC J, BACH M, LAGREZE W–Freiburg

- 265 Rarebit Fovea Test and OCT findings in diabetes  
NILSSON M, VON WENDT G, WANGER P, MARTIN L–Stockholm

- 266 The influence of pupil size, accommodation and higher order aberrations on the retinal image of a Rarebit Fovea Test-stimulus  
WAHLBERG M, BRAUTASET R, UNSO P, LINDSKOOG PETTERSSON A, NILSSON M–Stockholm

- 267 Foveal function in children treated for amblyopia  
AGERVI PH, NILSSON MA, MARTIN LM–Stockholm


- 268 Macular function in severe disbinocular amblyopia  
SHAMSHINOVA AM, SLYSHALOVA NN, KHVATOVA NV, SITNIKOVA DN–Moscow

- 269 Correctable and non-correctable refractive error in a population of young men in Poland  
NOWAK MS, GOS R, SMIGIELSKI J–Lodz

- 270 Functional characteristic of the retina in glaucoma  
KAZARYAN AA–Moscow

- 271 Function of macular area in retinopathy of prematurity  
SHAMSHINOVA AM, KATARGINA LA, KOGOLEVA LV, SITNIKOVA DN–Moscow





Thursday, October 4<sup>th</sup> -

# SOE 2009

THE 17<sup>TH</sup> CONGRESS OF THE EUROPEAN SOCIETY OF OPHTHALMOLOGY



NOG NEDERLANDS OOGHEEKUNDIG GEZELSCHAP

SOE 2009, 13-16 JUNE 2009  
AMSTERDAM, THE NETHERLANDS

[www.SOE2009.org](http://www.SOE2009.org)

## European University Professors of Ophthalmology EUPO 2008



**Annual Residents' Course**  
September 5-6, 2008 - Geneva, Switzerland  
Organization: Prof. A.B. Safran, Geneva University Eye Clinic

**Neuro-Ophthalmology and Strabismus**

The course will provide an overview and an update on recent advances in the above topics.

**Friday September 5, 2008**  
08:00 am - 06:00 pm, Neuro-Ophthalmology  
EUPO Party

**Saturday September 6, 2008**  
08:00 am - 06:00 pm, Strabismus

**Illustration:** The Old Clown, Van Dongen (1906)  
Musée du Petit Palais - Genève

[www.eupo.eu](http://www.eupo.eu)

# ng education in ophthalmology

17:30 - 19:00 - Emerald I



The European Board of Ophthalmology (EBO) Examination 2008 will take place on **May 9-10th, 2008** at the: **Palais des Congrès de Paris**, 2, Place Porte Maillot F-75017 PARIS FRANCE

**When?**  
May 9-10, 2008

**Where?**  
Paris, Palais des Congrès (Porte Maillot)

**Application period**  
From October 1, 2007 till January 1st 2008  
Electronic application form (website)

**More information...**  
<http://www.ebo-online.org>



**European Association for Vision and Eye Research**

**EVER 2008**

**October 1-4, 2008 - Portoroz, Slovenia**

[www.ever.be](http://www.ever.be)



10<sup>th</sup>  
anniversary congress



EWGR  
*Friday*  
*5 October*

Make your opinion count: attend the Section Business Meetings 19:00-20:00

<b>Europa A</b>	<b>Diagnostic imaging of the cornea</b>		08:30 – 10:00
SIS	Leonardo MASTROPASQUA, Harminder S DUA		

08:30	3111	Optical Coherence Tomography (OCT) and Ultrasonic Biomicroscopy in corneal diseases NUBILE M–Chieti
08:52	3112	Corneal topography and aberrometry: contribution to the ocular surface to visual optics VINCIGUERRA P–Milano
09:14	3113	In vivo confocal microscopy of the cornea GUTHOFF RF–Rostock
09:36	3114	Impression Cytology in corneal and ocular surface pathology DUA HS–Nottingham

<b>Europa B</b>	<b>Free Papers: Retinal vascular disease</b>	08:30 – 10:00
FP	Leopold SCHMETTERER, Leonidas ZOGRAFOS	

08:30	3121	Quantitative fluorescein angiograms SANTOS T, BERNARDES R, BAPTISTA P, SCHWARTZ A, CARTER W, CUNHA-VAZ J–Coimbra, San Juan, Groton
08:42	3122	Intermediate and combined forms of retinal telangiectasies ZOGRAFOS L–Lausanne
08:54	3123	Prognostic tools for visual acuity in primary rhegmatogenous retinal detachment ROLDAN-PALLARES M, MUSA AS, BRAVO-LLATAS C, HERNANDEZ-MONTERO J, FERNANDEZ-DURANGO R–Madrid
09:06	3124	Microstructural changes of longitudinal retinal venous profiles measured by retinal vessel analyzer in systemic hypertension KOTLIAR KE, NAGEL E, SEIDOVA SF, LANZL IM–Munich, Rudolstadt
09:18	3125	Diagnosis and follow-up of retinal detachment using a wide field scanning laser ophthalmoscope. ARNDT CF, NABHOLZ N, BAZALGETTE C, NGUYEN N–Montpellier
09:30	3126 rf	A new heavy internal tamponade in vitreoretinal surgery: an in vitro study MICHELONE L, FANNI D, FANTIN A, PAOLONI M, TOGNETTO D, RAVALICO G–Trieste
09:36	3127	Profile of the Spanish ophthalmologist dedicated to retinal pathology. Preliminary results SANCHEZ CHICHARRO DI, PASTOR JIMENO JC, FERNANDEZ I, ROJAS J–Valladolid

<b>Emerald I</b>	<b>Exfoliation and glaucoma</b>	08:30 – 10:00
SIS	Volkan DAYANIR, Anastasios G.P. KONSTAS	

08:30	3131	Epidemiology and clinical findings of exfoliation syndrome TSIRONI S–Thessaloniki
08:48	3132	New insights into pathophysiology of exfoliation SCHLOETZER SCHREHARDT U–Erlangen
09:06	3133	Blood flow changes in exfoliation DAYANIR V, TOPALOGLU A, OZSUNAR Y, KECELI M, OKYAY P, HARRIS A–Aydin, Indianapolis
09:24	3134	Current concepts in the management of exfoliative glaucoma KONSTAS AGP–Thessaloniki
09:42	3135	Management of co-existing cataract and exfoliation TEUS MA, DE BENITO-LLOPIS L–Madrid

Mediteranea I SIS	<b>Animal models of ocular inflammation</b> Bahram BODAGHI, Uwe PLEYER, Marc D DE SMET	08:30 – 10:00
08:30	3151 Experimental models of ocular inflammation: an overview BODAGHI B–Paris	
08:42	3152 Regulation of ocular inflammation--what experimental and human studies have taught us DE SMET M–Antwerp	
08:54	3153 Vasoactive intestinal peptide loaded in liposomes: a new immunomodulatory agent for the local treatment of experimental autoimmune uveoretinitis (EAU) CAMELO S, LAJAVARDI L, BOCHOT A, FATTAL E, GOLDENBERG B, NAUD MC, BEHAR-COHEN F, DE KOZAK Y–Paris, Châtenay-Malabry	
09:06	3154 Control of experimental uveoretinitis by specific or nonspecific regulatory T-cells TERRADA C, DE KOZAK Y, LEHOANG P, SALOMON B, BODAGHI B–Paris	
09:18	3155 Animal models of primary intraocular lymphoma TOUITOU V, BODAGHI B, DE KOZAK Y, LEHOANG P, FRIDMAN C, FISSON S–Paris	
09:30	3156 Immunopathogenesis of corneal graft rejection PLEYER U–Berlin	
09:42	General discussion	
Adria SIS	<b>Non-melanocytic conjunctival lesions</b> Mordechai ROSNER	08:30 – 10:00
08:30	3161 Non-melanocytic conjunctival epithelial lesions - overview ROSNER M–Tel-Hashomer	
08:45	3162 Long-term results of combined treatment with excision and cryosurgery for malignant epithelial tumors of the conjunctiva ALTAN-YAYCIOGLU R, PEKSAYAR G, ONAL S–Adana, Istanbul	
09:10	3163 The response of squamous cell carcinoma of the conjunctiva to treatment with photodynamic therapy BARBAZETTO IA, LEE TC, ABRAMSON DH–New York, Los Angeles	
09:35	3164 Topical 5-fluorouracil treatment and topical interferon alpha-2b treatment for conjunctival epithelial malignant lesions MIDENA E–Padova	

**Keynote Lecture**

10:15 – 10:55

**Europa A****Antigen-presenting cells and the eye**

Martine J JAGER, Leiden - The Netherlands

President ARVO

Introduction by Charlotta ALL-ERICSSON



<b>Europa A</b>	<b>Free Papers: Ocular surface and dry eye</b>		11:15 – 12:45
FP	Thomas WOOD, Jean-Jacques GICQUEL		
11:15	3211	Densitometry of meibometer samples from normal and dry eye subjects TIFFANY JM, LAVRIC A—Oxford, Ljubljana	
11:27	3212	Correlation between diagnostic tests guides the development and use of a dry eye diagnostic algorithm MOORE JE, GRAHAM JE, GOODALL E, DARLT DA, LECCISOTTI A, DOWNES S, MOORE CBT—Coleraine, Boston, Siena	
11:39	3213	Influence of platelets on the healing of dry eye of patients treated with topical eye drops of autologous Platelet-Rich Plasma (PRP) BATAILLE L, ALIO J, PASTOR S, KLONOWSKY P—Alicante, San Juan de Alicante	
11:51	3214	Nodular Degeneration WOOD TO, WILLIAMS EE, HAMILTON DL—Germantown	
12:03	3215	Watch out if you tell it with flowers: Euphorbia latex keratitis LANGMAN ME, DIGHIERO PL, GICQUEL JJ—Poitiers	
12:15	3216	Menstrual cycle influences ocular surface parameters in normal and dry eye patients VERSURA P, PROFAZIO V, COSLOVI C, CAMPOS EC—Bologna	
<b>Europa B</b>	<b>Inherited retinal disease: novel developments and treatment strategies</b>		11:15 – 12:45
SIS	Bart LEROY, Graham HOLDER		
11:15	3221	Retinal dystrophies & dysfunctions LEROY BP—Ghent	
11:37	3222	Macular dystrophies MOORE T—London	
11:59	3223	Treatment strategies SAHEL JA—Paris	
12:21	3224	Electrophysiology as a diagnostic tool HOLDER GE—London	
<b>Emerald I</b>	<b>Intraocular pressure fluctuations in glaucoma: myth or reality</b>		11:15 – 12:45
SIS	Nathalie COLLIGNON, Sanjay ASRANI		
<b>Alcon</b>			
11:15	3231	Circadian rhythm of intraocular pressure in healthy subjects and glaucoma patients ROMANET JP, PALOMBI K, NOEL C, CHIQUET C—Grenoble	
11:33	3232	Large intraocular pressure fluctuations: a risk factor for glaucoma progression ASRANI S—Durham, NC	
11:51	3233	When the IOP zigzag are combined with abnormal dipping of the arterial pressure curve COLLIGNON N, COLLIGNON J—Liège	
12:09	3234	Diurnal IOP curve versus 24-hour IOP curve: when and how to do it in practice KONSTAS AGP—Thessaloniki	
12:27	3235	Which glaucoma treatments best flatten the IOP fluctuations? ORZALESI N, FOGAGNOLO P—Milan, Rome	
<b>Europa A</b>	<b>THEA lunchtime CIS: New evaluation techniques in ocular surface diseases</b>		12:50 – 13:50
CIS			
<b>Théa</b>			
12:50	3271	Introduction	
12:55	3271	In vivo experimental evaluation of cornea using high frequency ultrasound device — PISELLA PJ—Boulogne	
13:05	3272	The new imaging techniques for assessing ocular surface diseases — KRUSE FE—Erlangen	
13:15	3273	A new experimental approach to early signs of eye irritation after acute and repeated exposures on HCE (in vitro reconstituted human corneal epithelium); an evaluation of effects of some multidose tear substitutes — MELONI M—Milano	
13:25	3274	Comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig — FERAUILLÉ L—La Gaude	
13:35		Discussion	

Emerald II SIS	<b>Duncan Symposium : Memory of George Duncan</b> Alfred WEGENER, Giovanni MARAINI		11:15 – 12:45
11:15	3241	Foundations of lens ion transport DELAMERE NA–Tucson, AZ	
11:30	3242	Calcium, the Universe and Everything SANDERSON J–Norwich	
11:45	3243	Sigma-1 receptor: a pivotal role in lens cell survival WANG L, DUNCAN G–Norwich	
12:00	3244	Calcium signalling can be bad for you: thapsigargin and PCO prevention WORMSTONE IM, WANG L, DUNCAN G–Norwich	
12:15	3245	Growth factor signalling and regulation of lens cell differentiation MCAVOY JW, STUMP RW, ANG S, CHEN Y, LOVICU FJ–Sydney	
12:30	3246	Alpha-Crystallins and their role in cataract and other diseases HORWITZ J–Los Angeles	
<b>Mediterranea I Novel ophthalmic technologies V</b> SIS Tom MISSOTTEN			11:15 – 12:45
11:15	3251	Application of structured illumination techniques to corneal microscopy REQUEJO-ISIDRO J, PEREZ-ESCUDERO A, MARCOS J–Madrid	
11:33	3252	Three-dimensional high-speed optical coherence tomography for the investigation of the cornea and anterior eye-segments YASUNO Y–Tsukuba, Ibaraki	
11:51	3253	Optical coherence tomography of the choroid at 1050nm UNTERHUBER A, POVAZAY B, HERMANN B, HOFER B, SATTMANN H, DREXLER W–Cardiff, Vienna	
12:09	3254	Spectral domain OCT at 850 nm and OFDI at 1050 nm for retinal imaging in glaucoma and AMD patients DEN BOER J–Boston	
12:27	3255	Motion of the scattering sites in the ocular fundus during transpupillary thermotherapy ROVATI L, CATTINI S, VIOLA F, STAURENGHI G–Modena, Milano	
<b>Adria</b> SIS Jacob PE'ER			11:15 – 12:45
11:15	3261	Treating ocular surface squamous neoplasia by topical Mitomycin C FRUCHT-PERY J, PE'ER J–Jerusalem	
11:30	3262	Treating conjunctival primary acquired melanosis with atypia by topical Mitomycin C PE'ER J, FRUCHT-PERY J–Jerusalem	
11:45	3263	Using local carboplatin in the treatment of retinoblastoma DESJARDINS L–Paris	
12:00	3264	Using intravitreal methotrexate for treating vitreoretinal lymphoma PE'ER J, SIEGAL T, FRENKEL S–Jerusalem	
12:15	3265	The potential of iontophoresis in introducing methotrexate and carboplatin into the eye FRUCHT-PERY J, PE'ER J, DOMB AJ, ELJARRAT-BINSTOCK E–Jerusalem	
12:30		Questions and discussion	

<b>Europa A</b>	<b>Free Papers: Refractive surgery</b>		14:00 – 15:30
FP	Alejandra Eliana RODRIGUEZ, Harminder S DUA		
14:00	3311	Long-term results of LASIK in the correction of high myopia LINDBOHM NM, TUISKU IS, TERVO TM–Helsinki	
14:12	3312	Comparison of corneal aberrations after myopic LASEK and LASIK surgeries using two different excimer lasers CANADAS SUAREZ P, HERNANDEZ-VERDEJO J, ROMAN-GUINDO J, SANCHEZ-PINA J, TEUS MA–Madrid	
14:24	3313	Long-term stability of LASEK performed to correct myopia in thin corneas. TEUS MA, DE BENITO-LLOPIS L, ALVAREZ M, TORRES J, GIL-CIGANDA N–Madrid	
14:36	3314	Stromal response to orthokeratology: an X-ray diffraction study OWENS H, HAYES S, MEEK KM–Auckland, Cardiff	
14:48	3315	Diclofenac effect on conjunctival goblet cells density after LASIK RODRIGUEZ AE, RODRIGUEZ-PRATS JL, MEZQUIDA G, ALIO JL–Alicante	
15:00	3316	LASIK-dry eye: fact or fancy REGINALD AY, TIFFANY JM, ROSEN PH, BRON AJ–Oxford	
<b>Europa B</b>	<b>Free Papers: Antiangiogenic treatments</b>		14:00 – 15:30
FP	Peter WIEDEMANN, Anita LEYS		
14:00	3321	Placental growth factor (PIGF) inhibition reduces choroidal neovascularization in a mouse model for age-related macular degeneration VAN DE VEIRE S, MOONS G, VINORES SA, CARMELIET P, STALMANS I–Leuven, Baltimore	
14:12	3322	Safety of Macugen (pegaptanib sodium) for neovascular age-related macular degeneration (NV-AMD). After 3 years of experience LEYS A, VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (V.I.S.I.O.N.)–Leuven	
14:24	3323	The PERSPECTIVES Study: pegaptanib efficacy results in multicenter, open-label study (Phase 3b/4) of early CNV in neovascular AMD over time, including vision function and QoL endpoints HEJSEK L, PERSPECTIVES STUDY GROUP–Prague	
14:36	3324	Anti-TNF-alpha therapy for exudative ARMD MISSOTTEN T, BAARSMA GS, VINGERLING JR, MARTINEZ-CIRIANO JP, VAN HAGEN PM–Rotterdam	
14:48	3325	Intravitreal bevacizumab in the treatment of refractory uveitic macular edema-A one year follow up observational study GALLAGHER MJ, CERVANTES-CASTANEDA RA, YILMAZ T, FOSTER CS–Boston	
15:00	3326	Efficacy and safety of pegaptanib sodium for macular edema secondary to Central Retinal Vein Occlusion (CRVO) WIROSTKO B, MACUGEN RETINAL VEIN OCCLUSION STUDY GROUP–Survey	
<b>Emerald I</b>	<b>What can we do more? Neuroprotection in glaucoma</b>		14:00 – 15:30
SIS	Ingeborg STALMANS		
 ALLERGAN			
14:00	3331	What have we learned about neuroprotection in the lab? WHEELER LA, HARE WA, DONG CJ–Irvine	
14:22	3332	How to watch ganglion cells in the DARC? CORDEIRO MF–London	
14:44	3333	How to monitor visual field progression? VISWANATHAN A–London	
15:06	3334	Does neuroprotection work in our patients? GANDOLFI S–Parma	

**Keynote Lecture**

15:45 – 16:25

**Europa A****New perspectives in retinal imaging:  
fundus autofluorescence and age-related macular degeneration**

Frank G. HOLZ, Bonn - Germany

Introduction by Charles RIVA



<b>Emerald II</b>	<b>Making sense of bilateral cataract surgery</b>		14:00 – 15:30
SIS	Christopher LIU		
14:00	3341	Making sense of immediately sequential bilateral phacoemulsification LIU C–Brighton	
14:22	3342	Biometry issues SMITH G	
14:44	3343	Disruption of binocular vision following cataract surgery WHITE J–Brighton	
15:06	3344	Health economics issues LEIVO T–Helsinki	
<b>Mediteranea I</b>	<b>Free Papers: Lens, Iris and Retina</b>		14:00 – 15:30
FP	Jan-Olof KARLSSON, Constantin POURNARAS		
14:00	3351	Acute effects of the sigma-2 receptor agonist siramesine on lens epithelial cells KARLSSON JO, JONHEDE S, PETERSEN A, ZETTERBERG M–Göteborg	
14:12	3352	Dose dependence of alpha-tocopherol protection against in vivo ultraviolet radiation and associated alterations in lens redox balance JING W, LÖFGREN S, DONG X, ZHANG Y, MODY V, AYALA M, MEYER L, GALICHANIN K, SÖDERBERG PG–Stockholm	
14:24	3353	The presence of an active ETB1 receptor is essential for ETB2 induced relaxation of the iris sphincter muscle ROCHA DE SOUSA A, ALVES-FARIA P, SARAIVA J, AMARAL M, FALCAO-REIS F, LEITE-MOREIRA A–Porto	
14:36	3354	TNF-alpha and Interferon-gamma upregulate AQP4 protein expression in ARPE-19, a human retinal pigmented epithelial cell line. JANSSENS S, CASPERS L, WILLERMAIN F, DELPORTE C–Brussels	
14:48	3355	Efflux proteins of outer blood-retinal barrier MANNERMAA E, VELLONEN KS, RYHÄNEN T, KAARNIRANTA K, URTTI A–Kuopio, Helsinki	
15:00	3356	Erythropoietin (epo) and the survival of retinal cells in diabetic retinopathy DE SOUZA RAMALHO P, PEREIRA DA SILVA A, BICHO MP–Lisbon	
<b>Adria</b>	<b>Free Papers: Oncology / Pathology 2</b>		14:00 – 15:30
FP	Charlotta ALL-ERICSSON, Steffen HEEGAARD		
14:00	3361	Imaging of iris melanotic lesions and corneal tumors with three different high speed optical coherence tomography instruments DE KEIZER RJW, RAZZAQ L–Leiden	
14:12	3362	Conjunctival melanoma & histone deacetylase inhibitors MADIGAN MC, CUNNEEN TS, NAREYECK G, ANASTASSIOU G, CONWAY RM–Sydney, Essen	
14:24	3363	In vivo GFP imaging of dormant liver metastasis in a human uveal melanoma mouse model FERNANDES BF, LOGAN P, DI CESARE S, ANTECKA E, MARSHALL JC, BURNIER JR. MN–Montreal	
14:36	3364	Clinicopathologic analysis in nasolacrimal canal obstruction ALTAN-YAYCIOGLU R, CANAN H, BAL N, SIZMAZ S, PELIT A, AKOVA YA–Adana, Ankara	
14:48	3365	Meningeal carcinomatosis - a hidden cause of bilateral visual loss HENC-PETRINOVIC LJ, JURIC A, VUKAS D, PETRINOVIC-DORESIC J–Zagreb, Sibenik	
15:00	3366	Lacrimal gland adenocarcinoma GARCIA-ALVAREZ C, SANCHEZ-MANNARELLI F, BLANCO-MATEOS G, BORREGO H, ESTEBAN R–Valladolid	
15:12	3367	Unusual recurrent orbital tumour IRION LD, BONSHEK R, ATAULLAH S, LEATHERBARROW B, MCKEAG D, FERNANDO B–Manchester	

**Poster session 2**

16:30 – 17:25

**Europa C**

Posters on pages 44-45

**Lens/Cataract - Pathology/Oncology - Retina/Vitreous**Jan-Olof KARLSSON, Alfred WEGENER - Jan Ulrik PRAUSE, Murat TUNC - Charles RIVA,  
Jean-Jacques DE LAEY, Einar STEFANSSON

<b>Europa A</b>	<b>Free Papers: Cornea</b>		17:30 – 19:00
FP	Rimvydas ASOKLIS, Harminder S DUA		
17:30	3411	Intracorneal bevacizumab for treating corneal neovascularization in an experimental rabbit model PERIS-MARTINEZ C, ALCOCER-YUSTE P, SANCHO-TELLO M, AVINO-MARTINEZ J, MARTINEZ-BELDA R, MENEZO JL, ROMERO FJ, BOSCH-MORELL F–Valencia	
17:42	3412	Amniotic membrane preservation in RPMI-1640 medium – 5 years experience ASOKLIS R, BUTKIENE L, JUODKAITE G, MAKSELIS A, MONTVILAITE D–Vilnius	
17:54	3413	Comparative analysis of donor derived, gene modified dendritic cells in keratoplasty PLEYER U, SCHLICKEISER S, LI XQ, RITTER T, SAWITZKI B–Berlin, Galway	
18:06	3414	A model for corneal endothelium specular microscopy images BUCHT C, SÖDERBERG PG–Stockholm	
18:18	3415 <i>rf</i>	Descemet membrane endothelial keratoplasty using descemetorhexis and organ-cultured donor corneal tissue MURAINÉ M, GARDEA E, TOUEAU D, BRASSEUR G–Rouen	
18:24	3416 <i>rf</i>	Ultrastructure of Femtosecond Laser trephination for keratoplasty VOSSMERBAEUMER U, KNORZ MC, JONAS JB–Mannheim	
<b>Europa B</b>	<b>Retinal image analysis and quantitative fluorescein angiograms</b>		17:30 – 19:00
SIS	Rui BERNARDES, Alfredo RUGGERI		
			
17:30	3421	A system to perform quantitative fluorescein angiography SCHWARTZ A–San Juan	
17:50	3422	Instrumentation adaptation for quantitative fluorescein angiograms BERNARDES R–Coimbra	
18:10	3423	Recent advances in the analysis of non vascular features in retinal images RUGGERI A, FIORIN D–Padova	
18:30	3424	Advances in the detection of the retinal vasculature HUNTER A, AL DIRI B–Lincoln	
<b>Emerald I</b>	<b>Free Papers: Intraocular pressure and treatment</b>		17:30 – 19:00
FP	Thierry ZEYEN, Mona PACHE		
17:30	3431	Is corneal hysteresis an additional risk factor for glaucoma? POURJAVAN S, BERKOUK K, DETRY- MOREL M–Brussels	
17:42	3432	Comparison of Icare, dynamic contour tonometer, and ocular response analyzer with goldmann applanation tonometer VANDEWALLE E, STALMANS I, VANDENBROECK S, ZEYEN T–Leuven	
17:54	3433	Central corneal thickness and glaucoma in adult chinese. The Beijing eye study JONAS JB, XU L, ZHANG H, WANG Y–Beijing	
18:06	3434	Monitoring individual compliance in glaucoma patients used to topical therapy BRON AM, HERMANN M, CREUZOT-GARCHER C, DIESTELHORST M–Dijon, Cologne	
18:18	3435	Deep sclerectomy in normal tension glaucoma SUOMINEN S, HARJU M, IHANAMAKI T, VESTI E–Helsinki	
18:30	3436	Trabeculectomy with or without adjustable flap sutures and anterior chamber maintainer ZEYEN T, VANDEWALLE E, RENIER C, VAN DE VEIRE S, STALMANS I–Leuven	
19:00 – 20:00 <b>Business Meetings of the scientific sections:</b>			
<b>Agenda</b> <ol style="list-style-type: none"> <li>1. Report of the scientific officer</li> <li>2. Report of the programme secretary</li> <li>3. Next year's meeting:           <ul style="list-style-type: none"> <li>• nomination of a section programme secretary</li> <li>• proposals of Special Interest Symposia (SIS)</li> </ul> </li> <li>4. Comment on the EVER activities</li> <li>5. Contact with Eastern Europe including Russia</li> <li>6. Other business</li> </ol>			
In addition to the agenda, the sections <b>Lens and Cataract</b> and <b>Retina / Vitreous</b> will nominate candidates for scientific officer.			

<b>Emerald II</b>	<b>Oxidative stress in the lens</b>	17:30 – 19:00
SIS	Anders BEHNDIG	
17:30	Introduction Marjorie F LOU by Per Söderberg	
17:35	3441 Oxidation damage repair in the lens: Thioltransferase and Thioredoxin systems LOU MF–Lincoln	
17:55	Discussion	
18:00	3442 Redox regulation of the proteasome in human lens epithelial cells and intact mouse lens PETERSEN A, CARLSSON T, KARLSSON JO, ZETTERBERG M–Göteborg, Mölndal	
18:12	3443 Enhanced diabetic cataract in mice lacking Cu-Zn superoxide dismutase OLOFSSON EM, MARKLUND SL, BEHNDIG A–Umeå	
18:24	3444 Oxidative inactivation of the proteasome and its consequences in lens biology SHANG F–Boston	
18:36	3445 Reduced and oxidized glutathione and TT-ase activity in mouse lens after in vivo exposure to ultraviolet radiation MEYER L–Stockholm	
18:48	3446 Dose-response relationship for alpha tocopherol associated protection of ultraviolet radiation induced cataract WANG J–Stockholm	
<b>Mediterranea I</b>	<b>Free Papers: Bloodflow and oxygenation</b>	17:30 – 19:00
FP	Herbert REITSAMER, Gerhard GARHOFER	
17:30	3451 Strategies for improving intraindividual reproducibility in laser Doppler flowmetry measurements PEMP B, MAAR N, WEIGERT G, LUKSCH A, RESCH H, GARHOFER G, ORGUL S, SCHMETTERER L–Vienna, Basel	
17:42	3452 Effect of Travoprost and Brinzolamide on ocular hemodynamics STALMANS I, VANDEWALLE E, VANBELLINGHEN V, ZEYEN T–Leuven	
17:54	3453 Effects of moxaverine and placebo on ocular blood flow GARHOFER G, RESCH H, WOLZT M, SCHMETTERER L–Vienna	
18:06	3454 Patients with coronary heart disease show reduced dynamic retinal arterial reaction LANZL IM, ALI M, SCHMIDT-TRUCKSAESS A, HALLE M, PRESSLER A, KOTLIAR KE–Munich	
18:18	3455 Oxygen gradients in the anterior segment of the eye REITSAMER HAR–Salzburg	
18:30	3456 Retinal oxygen saturation in humans in light and dark HARDARSON SH, JONSDOTTIR TE, BASIT S, HALLDORSSON GH, KARLSSON RA, BEACH JM, EYSTEINSSON T, BENEDIKTSSON JA, STEFANSSON E–Reykjavík	
<b>Adria</b>	<b>The anophthalmic socket</b>	17:30 – 19:00
SIS	Daniel BRISCOE, Brian LEATHERBARROW	
17:30	3461 Exenteration: Indications, techniques, and results of treatment LEATHERBARROW B–Manchester	
17:42	3462 Exenteration enucleation and evisceration: trends and dilemmas in pathology BONSHEK R–Manchester	
17:54	3463 Strategies to prevent anophthalmic socket contraction in retinoblastoma patients TUNC M–Duzce	
18:06	3464 Conditions for an ideal socket HAMEDANI M–Lausanne	
18:18	3465 Retinoblastoma and the Anophthalmic socket reconstruction WILSHAW H–Birmingham	
18:30	3466 Overview of therapeutics for improving the orbital volume in the socket syndrome MOURIAUX F–Caen	
18:42	3467 Reconstruction of the congenital anophthalmic/cryptophthalmic socket BRISCOE D, VARDIZER M–Kfar Saba, Haifa	

**Lens and Cataract****Moderators:****Jan-Olof KARLSSON, Alfred WEGENER**

- 301 Estimation of a safety limit for ultraviolet radiation-B (UVR-B)-induced cataract in an *in vivo* pigmented guinea pig model  
MODY VCJR, KAKAR M, DONG X, ZHANG Y, HUANG S, GALICHANIN K, LÖFGREN S, SÖDERBERG PG–Stockholm
- 302 Age dependence of cataract induced by ultraviolet radiation-B in mice  
ZHANG Y, WANG J, DONG X, MEYER L, MODY V, LÖFGREN S, GALICHANIN K, SÖDERBERG PG–Stockholm
- 303 Safety limits estimation for ultraviolet radiation induced cataract in different age groups  
DONG X–Stockholm
- 304 A new universal rat restrainer for *in vivo* exposure to UVR without anesthesia  
GALICHANIN K, HUANG S, WANG J, ZHANG Y, MODY JVRC, LÖFGREN S, SÖDERBERG PG–Stockholm
- 305 Evolution of light scattering after *in vivo* close to threshold dose of ultraviolet radiation 300 nm  
HUANG S, GALICHANIN K, MODY V, LÖFGREN S, SÖDERBERG PG–Stockholm
- 306 Resolution visual fields in children surgically treated for congenital cataract  
MARTIN L, MAGNUSSON G, POPOVIC Z, SJÖSTRAND J–Stockholm, Gothenburg
- 307 Modeling fluid mixing within the crystalline lens during accommodation  
CHE S, HUNTER P, PHILLIPS JR, JACOBS M–Auckland
- 308 Ultrastructure features of lens epithelium in intumescent white cataract  
STUNF S, HVALA A, HAWLINA M–Ljubljana
- 309 Modulation transfer function in refractive-diffractive multifocal intraocular lenses *in vitro*  
PERIS-MARTINEZ C, ARTIGAS JM, MENEZO ROZALEN JL, FELIPE A, DIEZ AJENJO A–Valencia
- 310 Evaluation of the performance of multifocal intraocular lenses image quality: analysis of the standard methods  
MENEZO ROZALEN JL, ARTIGAS JM, FELIPE A, PERIS-MARTINEZ C–Valencia
- 311 High Order Aberrations of the eye implanted the Verisyse® iris-claw intraocular lens  
GICQUEL JJ, LANGMAN ME, NGUYEN KHOA JL, MERCI E, DIGIER PL–Poitiers, Suresne
- 312 Secondary IOL implantation without capsular support. A laser flare cell-meter study  
BRAVETTI GO, LEONETTI P, MANDRIOLI M, STROBBE E, CELLINI M, CAMPOS EC–Bologna
- 313 Pseudophakic dysphotopsia associated with the implantation of intraocular lenses  
SKUNCA JS, PETRIC VICKOVIC IPV, LACMANOVIC LONCAR VLL, BEDNAR IB, DOKO MANDIC BDM, MANDIC ZM–Zagreb
- 314 Pain in the different stages of cataract surgery by phacoemulsification technique in topical anaesthesia  
KALMAN R, GOMBOS K, NAGY ZZS–Budapest
- 315 Anterior chamber depth changes and complications after Nd:YAG laser treatment for posterior capsule opacification in pseudophakic eyes  
EVCIMAN T, OZKURT Y, SENGORT, HABOGLU M, KURNA S, AKI S–Istanbul
- 316 Surgical outcome following iris related intraoperative difficulties in patients on tamsulosin (Flomax) undergoing phacoemulsification  
KANG CY, KHAN-LIM D, UNG T, LOCKWOOD A, FARNWORTH D–Portsmouth, Southampton, Sheffield
- 317 Elastic modulus of the iris with drug stimulation  
KOTLIAR KE, WHITCOMB J, BARNETT V, OLSEN T, BAROCAS V–Munich, Minneapolis


**Pathology/Oncology****Moderators:****Jan Ulrik PRAUSE, Murat TUNC**

- 318 Ocular conservation in patients with uveal melanoma by a multimodality approach to treatment  
GARCIA-ALVAREZ C, SAORNIL MA, MUÑOZ MF, ALMARAZ A, LOPEZ-LARA F, MUÑOS Y, FRUTOS J–Valladolid
- 319 Quality assurance in episcleral brachytherapy  
DE FRUTOS-BARAJA JM, SAORNIL MA, GARCIA-ALVAREZ C, RUIZ-BUENO A, CEBALLOS-GARCIA A, MUÑOS Y, LOPEZ-LARA F–Valladolid
- 320 Immune expression and inhibition of HSP90 in uveal melanoma  
FAINGOLD D, MARSHALL JC, ANTEKA E, DI CESARE S, BAKALIAN S, BURNIER MN–Montreal
- 321 The effect of Blue-Light exposure in an ocular melanoma animal model  
FERNANDES BF, DI CESARE S, MALONEY S, MARSHALL JC, DAWSON WW, BURNIER MN–Montreal, Gainesville
- 322 AML with bilateral retinal detachment  
SARKADY E, JONES NP, BONSHEK R–Manchester
- 323 Non Hodgkin orbital lymphoma  
KNEZEVIC T, IVEKOVIC R, MANDIC Z–Zagreb
- 324 Mechanisms of secondary glaucoma in eyes with advanced retinoblastoma: histopathological  
HADJISTILIANOU T, FREZZOTTI P, MENICACCI F, MITICA V–Siena
- 325 Autofluorescence and histological findings in cancer-associated retinopathy caused by small cell lung carcinoma  
SKET KONTESTABILE A, BRECELJ J, PIZEM J, ADAMUS G, HAWLINA M–Ljubljana, Oregon
- 326 Management of dumbbell-shaped dermoid cysts in the temporal fossa and orbit  
MISSOTTEN GS, DE KEIZER RJW–Leiden
- 327 Oncocytic adenocarcinoma of lacrimal gland with GCDFP15 positivity  
TOSOUNIDIS I, BONSHEK RE, LEATHERBARROW B, LANE C–Manchester, Cardiff
- 328 Silent squamous cell carcinoma invaded into the orbit via the perineural space of the zygomatic-temporal nerve  
DE KEIZER RJW, SLIJMERS J, DE WOLFF ROUENDAAL D–Leiden, The Hague
- 329 Use of Mitomycin C in the treatment of conjunctival and corneal squamous cell carcinoma. a case report  
CELLINI M, LEONETTI P, STROBBE E, CAMPOS EC–Bologna

**Retina/Vitreous****Moderators:****Charles RIVA, Jean-Jacques DE LAEY, Einar STEFANSSON**

- 330 A new heavy internal tamponade in vitreoretinal surgery: an in vitro study  
*r/f* MICHELONE L, FANNI D, FANTIN A, PAOLONI M, TOGNETTO D, RAVALICO G-Trieste
- 331 Use of a wide field scanning laser ophthalmoscope for screening purposes  
ARNDT C, NABHOLZ N, GUERIN M, BAZALGETTE C, RENARD E, AVIGNON A, NGUYEN F-Montpellier
- 332 Morphological and functional analyses of diabetic macular edema in diurnal fluctuation by optical coherence tomography and fundus related microperimetry in patients with type 1 diabetes  
CARNOVALE SCALZO G, RECHICHI M, SCORCIA GB, AHMETAJ M, LEONE A, PAOLA A, BRUZZICHESI D, SCORCIA V, ALOI M, SCORCIA G-Catanzaro
- 333 The assessment of retinal layer thickness and volume segmentation reproducibility of optical coherence tomography images  
TATRAI E, SOMFAI GM, FERENCZ M, PULIAFITO CA, CABRERA FD-Budapest, Miami
- 334 Segmentation analysis of the age related retinal changes in patients with achromatopsia  
VARSANYI B, LESCH B, VA'MOS R, FARKAS A-Budapest
- 335 The grey fovea sign of foveal edema or serous detachment on non-stereoscopic digital red-free fundus photographs  
PASCAL HASLER, SOLIMAN WS, SANDERS BS, HAAMANN PH, LARSEN ML-Glostrup
- 336 The analysis of fundus autofluorescence patterns in retinal diseases  
POPOVIC P, JARC - VIDMAR M, HAWLINA M-Ljubljana
- 337 Ocular and systemic factors associated with diabetes mellitus in the adult population in rural and urban China. The Beijing eye study  
JONAS JB, XU L, XIE X, WANG Y-Beijing
- 338 Ultrastructure of diabetic epimacular tissue  
SYNEK S, PAC L, SYNEKOVA M-Brno
- 339 Correlation between fluorescein angiography and optical coherence tomography in diabetic macular edema  
GARCIA CAMPOS JM-Málaga
- 340 The sensitivity of OCT in the diagnosis of clinically significant macular edema  
VAN DIJK HW, KOK PHB, ABRAMOFF MD, SCHLINGEMANN RO, BERNARDES R, VERBRAAK FD-Amsterdam, Iowa city, Coimbra
- 341 A preliminary study of cell therapy of diabetic retinopathy in mice with experimental-induced diabetes  
LAZUK AV, ZEMCHIKHINA VN, GOLUBEVA ON, ERNST LK, BUDULEVA IA-Moscow
- 342 Validity of non-mydriatic cameras for screening and follow-up in diabetic retinopathy  
IBANEZ J, MATEO A, FAURE E, CRISTOBAL JA, DEL BUEY MA, MINGUEZ E, NUNEZ E, ASCASO Fj-Zaragoza
- 343 Posterior sub-tenon triamcinolone acetonide for the treatment of diabetic macular edema  
OZKURT Y, EVCIMANT T, HABOGLU M, SENGOR T, KURNA S, AKI S-Istanbul
- 344 Association of single nucleotide polymorphisms (SNPs) of VEGF gene with diabetic retinopathy  
LIINAMAA MJ-Oulu
- 345 Intravitreal Triamcinolone Acetonide to control the diabetic macular edema  
SANCHEZ CHICHARRO D, LOPEZ GALVEZ MI-Valladolid
- 346 Retinal layer thickness changes in eyes with diffuse diabetic macular edema  
SOMFAI GM, TATRAI E, FERENCZ M, PULIAFITO CA, CABRERA FD-Budapest, Miami
- 347 IL-8 vitreous levels in proliferative diabetic retinopathy  
GLOBOCNIK PETROVIC M, KOSNIK M, KOROSEC P, HAWLINA M-Ljubljana, Golnik
- 348 Fundus autofluorescence pattern as risk factor for development of geographic atrophy in patients with age-related maculopathy  
MOESSNER A, HOLZ FG, FOJA C-Leipzig, Bonn
- 349 Training improves the identification of Retinal Angiomatous Proliferation in the UK network of ophthalmic reading centres  
PATTON WP, PETO T, MULDREW KA, REEVES B, LENFESTY P, HARDING SP, STEVENSON M, CHAKRAVARTHY U-Belfast, London, Liverpool

- 350 Grading for progression of Age Related Macular Degeneration in the London AMD Study  
PETO T, SALLO FS, DANDEKAR S, LEUNG I, XING W, BUNCE C, BIRD AC-London
- 351 Glycoproteins of drusen and drusen-like lesions  
BONSHEK RE, D'SOUZA Y, JONES C-Manchester, London
- 352 The role of telemedicine in improving the referral service for consideration of treatment for age-related macular degeneration in a tertiary referral centre  
D'SOUZA Y, TUFAIL A-London
- 353 Risk factors for age related maculopathy in a Tunisian population  
EL MATRI L, BOURAOUI R, BAKLOUTI K-Tunis, Nabeul
- 354 Full field ERG values before and after anti-VEGF treatment in AMD affected subjects  
VARANO L, CAMPAGNA F, RUSSO C, SCORCIA V, SCORCIA GB, BRUZZICHESI D, PARISE S, CARNOVALE SCALZO G, SCORCIA G-Catanzaro
- 355 Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes  
RUIZ MORENO JM, MONTERO-MORENO JA, AMAT-PERAL P, LUGO F, STAICU C, DE LA VEGA C-Alcante
- 356 Effects of sodium pegaptanib intravitreal therapy in subjects affected by wet age-related macular degeneration not-responsive to photodynamic therapy: angiographic, OCT and microperimetric data  
PARISE S, RANDAZZO G, VARANO L, CARNOVALE SCALZO G, RECHICHI M, PAOLA A, SCORCIA V, SCORCIA GB, BRUZZICHESI D, SCORCIA G-Catanzaro
- 357 Effects of autologous translocation of the choroid and retinal pigment epithelium on the retinal light response in patients with neovascular age-related macular degeneration  
LÜKE C, KOCH A, KUTZER J, LÜKE M, JOERES S, JOUSSEN AM, KIRCHHOF B-Cologne, Tübingen, Düsseldorf
- 358 A case of lead toxicity and associated maculopathy  
PIERCE CO, BOOTH AJ-Cosham
- 359 Optical coherence tomography in patients with cone-rod dystrophy  
VA'MOS R, VARSANYI B, LESCH B, FARKAS A-Budapest
- 360 Foveal damage volume and visual acuity in solar retinopathy  
LARA MEDINA J, ISPA CALLEN C, GONZALEZ DEL VALLE F-Alcazar de San Juan
- 361 Results of optical coherent tomography in children with myopia  
BOYCHUK IM, IVANICKAYA EV- Odessa
- 362 Scleroplasty with posterior pole buckling for the treatment of high myopia  
TARUTTA EP, MARKOSSIAN GA, IOMDINA EN, IVASHCHENKO ZHN, KRIZHKOVA GV-Moscow
- 363 Photodynamic therapy in myopic eyes with CNV with marked leakage  
CATALANO C, RANDAZZO G, PARISE S, SCORCIA V, SCORCIA G-Catanzaro
- 364 The vasodilatory effect of juxta-arteriolar microinjection of endothelin-A receptor inhibitor in healthy and in acute branch retinal vein Occlusion Minipig Retinae  
POURNARAS CJ, STANGOS AN, POURNARAS JAC, PETROPOULOS IK-Geneva, Lausanne
- 365 Early treatment favours the anatomical outcome of ROP  
BOSKOS G, KOZEIS N, TIGANITA S, AGGELIDOU E-Thessaloniki
- 366 The retinal vessel response to flicker light in patients with central retinal vein occlusion  
REHAK M, REHAK J, LANGOVA K, WIEDEMANN P-Leipzig, Olomouc
- 367 Thrombophlebitis and bilateral visual loss and in Behcet's disease  
DORE S, DEVILLA L, SALVO M, DESOLE L, PATTERI P-Sassari, Nuoro
- 368 980 nm Diode laser retinochoroidal photocoagulation – in vitro comparison with frequency doubled Nd:YAG (532 nm) laser  
URBANCIC M, MOČNIK G, PIZEM J, DRNOVSEK-OLUP B-Ljubljana
- 369 Trace elements in the retina of eyes enucleated due to complications of a severe trauma  
IOMDINA EN, FILATOVA IA, KHOROSHEVA EV-Moscow
- 370 Effect of intravitreal injection of indocyanine green, triamcinolone acetonide and trypan blue on the electroretinographic response in the rat  
GARCHER CREUZOT C, ACAR N, GUILLAUBEY A, BIDOT S, PASQUIS B, JOFFRE C, BRON AM, BRETILLON L-Dijon



10<sup>th</sup>  
anniversary congress



Saturday  
6 October

07

Make your opinion count: attend the General Assembly & Prize Giving 18:05-19:00

<b>Europa A</b>	<b>Corneal transplantation: layer by layer</b>			08:30 – 10:00
SIS	Philippe KESTELYN, Ilse CLAERHOUT			
08:30	4111	Reconstruction and replacement of the ocular surface DUA HS–Nottingham		
08:48	4112	The DSAEK development and its modification for improved endothelial survival BUSIN M–Forlì		
09:06	4113	DLEK to DSEK to DMEK MELLES GRJ, ONG TS, VERVERS B, VAN DER WEES J–Rotterdam		
09:24	4114	PKP versus LKP: rehabilitation speed, optical performance, endothelial cell loss KESTELYN P, CLAERHOUT I–Ghent		
09:42	4115	The role of the Femtosecond (FS) laser in lamellar keratoplasty NUYTS RMMA, CHENG YY, PELS E, THE DUTCH LAMELLAR CORNEAL TRANSPLANTATION STUDY GROUP–Maastricht		
<b>Europa B</b>	<b>ARMD : additional examinations critically reviewed</b>			08:30 – 10:00
SIS	Tom MISSOTTEN, Louise O'TOOLE			
08:30	4121	Fluorescein and ICG angiograms : still a gold standard O'TOOLE L–Dublin		
08:45	4122	Reproducibility of OCT in choroidal neovascularization secondary to ARMD MENCHINI F, PARRAVANO C, ROMAN POGNUZ D, MORGANTE L, VARANO M, BANDELO F–Udine, Roma		
09:00	4123	Phenotype-Genotype correlations : more than identifying risks ? AUDO I, LEVEILLARD T, SAHEL JA–Paris		
09:15	4124	Autofluorescence : additional value in clinical management of ARMD VACLAVIK V, BIRD AC–London		
09:30	4125	Microperimetry : understanding what went wrong or predicting therapeutic routes VUJOSEVIC S–Rome		
09:45	4126	(Multifocal) ERG : additional functional information in research and clinical settings TSANG SH, SANTOS R, GREENSTEIN VC–New York		
<b>Emerald I</b>	<b>Free Papers: Diagnosis and progression</b>			08:30 – 10:00
FP	Gabor HOLLO, Kivanc GUNGOR			
08:30	4131	SITA-SWAP in glaucoma diagnosis MILANO G, BOSSOLESI L, MACERI C, COLOMBO M, BORDIN M, SERRA U–Pavia		
08:42	4132	Accuracy of scanning laser polarimetry, scanning laser tomography in a glaucoma screening trial HOLLO G, TOTH M, KOTHY P–Budapest		
08:54	4133	Cup reversal protects from glaucoma progression HARJU M, SAARI J, KURVINEN L, VESTI E–Helsinki		
09:06	4134	Combination of structural and functional methods for the diagnosis and follow-up of glaucoma:results of a two-year-study SKORKOVSKA SS, MICHALEK JM–Brno		
09:18	4135	Morphologic factors associated with progressive glaucomatous optic disc damage in patients with primary open angle glaucoma and low tension glaucoma LAEMMER R, HORN FK, JUENEMANN AGM, MARDIN CY–Erlangen		
09:30	4136 rf	Structure-function relationship in the process of primary open-angle glaucoma - an OCT study AJTONY CS, BALLA ZS, KOVACS B–Pécs		

**Ophthalmic Research Lecture**  
10:15 – 10:55  
**Europa A**

**Active subretinal implants in seven blind patients:  
outcome of a pilot study and further developments**  
Eberhart ZRENNER, Tübingen - Germany  
Introduction by Werner SPIELEERS



Announcement of the winner of the inaugural European Vision Award



details on page 59



<b>Emerald II</b>	<b>Ocular straylight measurement</b>		08:30 – 10:00
SIS	Ralph MICHAEL, Tom VAN DEN BERG		
 <b>sponsored</b>			
08:30	4141	Basics of straylight in the human eye VAN DEN BERG TJTP–Amsterdam	
08:45	4142	Glare as parameter of quality of sight TASSIGNON MJ, ROZEMA JJ–Antwerp	
09:00	4143	Intraocular straylight and contrast sensitivity after LASIK MICHAEL R, OSPINO A, GIOINO J, RECANCOF A, BARRAQUER RI–Barcelona	
09:15	4144	Straylight after cataract operation GRABNER G, MARVAN M–Salzburg	
09:30	4145	Straylight induced by changes in the vitreous DE SMET M–Antwerp	
09:45	4146	C-quant for clinical screening ASPINAL PA, DHILLON B, HILL AR, GRAVES R–Edinburgh	
<b>Mediteranea I ISCEV session</b>			08:30 – 10:00
Joint M.	Colin BARBER		
			
08:30	4151	The EVI-genoret phenotype / genotype patient data base: a pan-European tool for retinal dystrophies and age related macular degeneration ZRENNER E, WILKE R, TROEGER E, AYUSO C, VALLESPIN E, SILVA E, SCHOLL HP, BELLMANN C, RIPP R, POCH O, CUNHA-VAZ J, SAHEL J, CHAKRAVARTHY U, MOORE T–Tübingen, Madrid, Coimbra, Bonn, Paris, Illkirch Strasbourg, Belfast, London	
08:52	4152	Electrophysiology and autofluorescence imaging in differential diagnosis of retinal and optic nerve disease HAWLINA M, JARC-VIDMAR M, POPOVIC P, BRECELJ J–Ljubljana	
09:14	4153	Relationship between visual acuity, visual evoked patterned potentials done at different spatial frequencies and fundus findings in more than 100 Cerebral Visual Impairment affected subjects RUBERTO G, BERTONE C, ANTONINI M, SIGNORINI S, ANGELI R, LUPARIA A, FAZZI E, PEZZOTTA S, TINELLI C, BIANCHI PE–Pavia	
09:36	4154	A previously undescribed autosomal recessive retinal dystrophy HOLDER GE, BURGESS R, MILLAR ID, LEROY BP, URQHART JE, FEARON IM, DE BAERE E, BROWN PD, ROBSON AG, WRIGHT GA, KESTELYN P, WEBSTER AR, MANSON FDC, BLACK GC–London, Manchester, Ghent	
<b>Adria OOG: Papers</b>			08:30 – 10:00
Joint M.	Edoardo MIDENA		
			
08:30	4161	Atypical chalazion LOEFFLER K–Bonn	
08:40	4162	Subcutaneous upper eyelid lesion LOEFFLER K–Bonn	
08:50	4163	Monitoring corneo-conjunctival epithelial tumors: the in-vivo approach DE BELVIS V, MIDENA E–Padova	
09:00	4164	Flow cytometry in the diagnosis of OAL RADIN PP, MIDENA E–Padova	
09:10	4165	Bilateral choroidal melanoma NOVAK ANDREJCIC K, DRNOVSEK B, KRAUT A, MIDENA E	
09:20	4166	Mapping conjunctival tumors: a prospective study DAMATO B, COUPLAND S–Liverpool	
09:30	4167	Topical chemotherapy of conjunctival tumors: a reappraisal PE'ER J, MIDENA E–Jerusalem, Padova	
09:40	4168	MLPA of extraocular tumors COUPLAND S, DAMATO B–Liverpool	
09:50	4169	MLPA of uveal melanomas COUPLAND S, VAN DIJK M, SIBBRING J, HOWARD P, DAMATO B–Liverpool	

Europa A SIS	<b>Keratoprostheses 1</b> Christopher LIU	11:15 – 12:45
11:15	4211	Strampelli's osteo-odontokeratoprosthesis BARRAQUER J, TEMPRANO J, DE LA PAZ MF-Barcelona
11:33	4212	UK experience and evolving strategies to improve results I - clinical results PERERA S, OKERA S, TANDON R, HEROLD J, HULL C, THORP S, LIU C-Brighton
11:51	4213	UK experience and evolving strategies to improve results II - imaging FRANCIS I, HEROLD, HULL, LIU C-Brighton
12:09	4214	OOKP - the Singapore Experience WONG D, ET AL-Singapore
12:27	4215	Vitreoretinal management in osteo-odontokeratoprosthesis surgery WONG D-Singapore
Europa B FP	<b>Free Papers: Pathophysiology</b> Gisèle SOUBRANE, Einar STEFANSSON	11:15 – 12:45
11:15	4221	Why is geographic atrophy more common in Iceland than in other white populations. JONASSON F-Reykjavik
11:27	4222	Ten-year follow-up of drusen like lesions in mesangiocapillary glomerulonephritis II D'SOUZA Y, BONSHEK R, SHORT D-London, Manchester
11:39	4223	Reduced choroidal blood flow parameters play a role in the development of neovascular AMD WEIGERT G, SCHMETTERER L, LUKSCH A, MAAR N, ERGUN E, WIMPISSINGER B, GARHOFER G, FUCHSJAEGER-MAYRL G, STUR M-Vienna
11:51	4224	Local and multifocal ERG in age-related macular degeneration. ZOLNIKOVA IV, AHMEDZHANOVA EV, KARLOVA IZ, SHAMSHINOVA AM-Moscow
12:03	4225	Human choroidal endothelial cell growth factor signalling in age-related macular degeneration STEWART EA, BROWNING AC, AMOAKU WMK-Nottingham
12:15	4226	Effects of bevacizumab on HUVEC migration and capillary formation FALCÃO MA, SOARES R, AZEVEDO I, FALCÃO-REIS F, CARNEIRO A-Porto
Emerald I FP	<b>Free Papers: Blood flow</b> Selim ORGUL, Gabriele FUCHSJAEGER-MAYRL	11:15 – 12:45
11:15	4231	Variability of ocular perfusion measurements in glaucoma and healthy subjects FUCHSJAEGER-MAYRL G, SCHMETTERER L-Vienna
11:27	4232	Twelve hour variability of ocular blood flow parameters in healthy subjects and patients with primary open angle glaucoma SCHMETTERER L, GEORGOPoulos M, VASS C, LUKSCH A, FUCHSJAEGER-MAYRL G, GARHOFER G-Vienna
11:39	4233	Changed retinal capillary flow in patients with disc haemorrhages KURVINEN L, HARJU M, SAARI J, VESTI E-Helsinki
11:51	4234	Retrobulbar hemodynamics in normal tension glaucoma compared to anterior ischemic optic neuropathy REMKY A, KAUP M, AREND KO, PLANGE N-Aachen
12:03	4235	Disturbed vascular response of the central retinal artery during hypercapnia in normal tension glaucoma PLANGE N, KAUP M, HARRIS A, AREND KO, REMKY A-Aachen, Indianapolis, Alsdorf
12:15	4236 rf	Dynamic retinal vessel reaction in patients with primary open angle glaucoma SEDOVA SF, KOTLIAR KE, VON DÜRING C, LANZL I-Munich, Passau
12:21	4237 rf	Abnormal peripheral vascular response to occlusion provocation in normal tension glaucoma patients WIERZBOWSKA J, STANKIEWICZ A, BURSA P, MANIEWSKI R, LIBERT A, ZBIEC A, WOJKIEWICZ S, SIERDZINSKI J-Warsaw

<b>Emerald II</b>	<b>Epidemiology of cataract</b>	11:15 – 12:45
SIS	Per SÖDERBERG, Teodosio LIBONDI, Kazuyuki SASAKI	

11:15	4241	Quantitative cataract measurement SÖDERBERG P–Stockholm
11:27	4242	Quantification of light scattering and cataract development using the Scheimpflug's principle WEGENER AR–Bonn
11:39	4243	Cataract classification systems, a critical review SASAKI K–Uchinada
11:51	4244	Lens opacification in Icelanders 50 years and older, risk factors. Reykjavik eye study JONASSON F–Reykjavik
12:03	4245	Prevalence and risk factors of lens opacities in urban and rural chinese in Beijing JONAS JB, XU L, CUI T, ZHANG S, SUN B, ZHENG Y, HU A, LI J, MA K–Beijing
12:15	4246	Racial differences of lens transparency properties SASAKI H–Ishikawa-Ken

<b>Mediteranea I</b>	<b>How to get your work published ?</b>	11:15 – 12:45
Workshop	Uwe PLEYER, Pinar AYDIN, Andrew DICK, Jochen GRAW	

Junior researchers often face the challenge of getting their interesting work published. The goal of this course will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article.

The panelists will discuss major aspects of the editorial process including basic decisions: where to submit your work, how to organize and prepare a manuscript, lenghts of the review process, the revision process for re submission.

The panelists will raise the discussion on issues like:

- How to choose a journal ?
- How to organize your paper ?
- What are the characteristics of a good manuscript ?
- Delayed response: When is it appropriate to ask for the status of your manuscript ?
- How to interpret the letter from the editor ?
- How to write a good reply to the reviewers?
- What to do when your paper is rejected ?
- When can it be appropriate to request a reevaluation of a rejected paper ?

<b>Adria</b>	<b>Tumours and tumour-like lesions of the optic nerve</b>	11:15 – 12:45
SIS	Jan Ulrik PRAUSE, Dan MILEA	

11:15	Introduction by Jan Ulrik PRAUSE	
11:17	4261	Disk swelling - differential diagnosis in orbital space occupying lesions GUTHOFF R–Rostock
11:33	4262	Neuro-ophthalmological analysis and imaging of optic nerve tumours MILEA D–Copenhagen
11:49	4263	The use of VEP in the evaluation of optic nerve lesions HOLDER GE–London
12:05	4264	Histopathology of optic nerve tumours HEEGAARD S–Copenhagen
12:21	4265	A rare case – a diagnostic challenge PRAUSE JU–Copenhagen
12:37	Closing remark by Dan MILEA	

Europa A SIS	<b>Keratoprostheses 2</b> Christopher LIU		14:00 – 15:30
14:00	4311	Advances in the Type I Boston Keratoprosthesis COLBY K, DOHLMANN C–Boston, MA	
14:15	4312	Boston KPro collaborative study results BELIN MW–Albany, NY	
14:30	4313	An update on the AlphaCor CRAWFORD G, HICKS C–Perth	
14:45	4314	Where are we with the supra-Descemet KPro (Keralia)? LAMAR PD, ALFONSO E, STOIBER J, FERNANDEZ V, KAMINSKI S, LACOMBE E, DUCHESNE B, ACOSTA C, PAREL JM–Miami, Paris, Liège	
15:00	4315	An update on the synthetic collagenous artificial cornea FAGERHOLM P, GRIFFITH M–Linköping, Ottawa	
15:15	4316	Infection control in KPros NOURI M–Boston	
Europa B SIS	<b>Retinal pigment epithelium</b> Kai KAARNIRANTA, Hannu UUSITALO		14:00 – 15:30
			
14:00		Opening by Hannu UUSITALO	
14:10	4321	Retinal pigment epithelial cells under oxidative stress WELGE-LUSSEN U–Munich	
14:30	4322	Cellular responses to lysosomal dysfunction in RPE cells KOPITZ J–Heidelberg	
14:50	4323	Proteolysis in RPE cells KAARNIRANTA K–Kuopio	
15:10	4324	Regulation of complement activation in ocular and vascular inflammation SEPOO M–Helsinki	
Emerald I Workshop	<b>Neuro-ophthalmic foibles</b> Aki KAWASAKI, François-Xavier BORRUAT		14:00 – 15:30
14:00	4331	Clinical look-a-like KAWASAKI A–Lausanne	
14:22	4332	Misinterpretation of common ophthalmic tests BORRUAT FX–Lausanne	
14:44	4333	Radiologic pitfalls in neuro-ophthalmology MILEA D–Copenhagen	
15:06	4334	Management misadventures BOSCHI A–Brussels	

<b>Emerald II</b>	<b>Wavefront aberrometry and adaptive optics</b>		14:00 – 15:30
SIS	Jean-Jacques GICQUEL		

14:00	4341	The basics of wavefront aberrometry LANGMAN ME, DIGHIERO PL, GICQUEL JJ–Poitiers
14:18	4342	Applications of adaptive-optics in ophthalmology CHATEAU N–Orsay
14:36	4343	Sports and wavefront aberrometry GICQUEL JJ, DIGHIERO PL–Poitiers
14:54	4344	Limitations of correcting aberrations with soft contact lenses LOPEZ-GIL N, CASTEJON-MOCHON JF, BONAQUE S–Murcia, Segovia
15:12	4345	Wavefront guided custom ablation: facts and fiction NGUYEN KHOA JL–Paris

<b>Mediterranea I</b>	<b>Matrix metalloproteinases in vascular and ocular disease</b>	14:00 – 15:30
SIS	Leopold SCHMETTERER	



14:00	4351	MMPs in vascular disease WOLZT M–Vienna
14:22	4352	MMPs in ocular physiology EICHHORN M–Erlangen
14:44	4353	MMPs in CNV LAMBERT V, RAKIC JM, NOEL A, FOUDART JM–Liège
15:06	4354	MMPs in glaucoma SCHLOETZER SCHREHARDT U–Erlangen

<b>Adria</b>	<b>OOG: Protocols</b>	14:00 – 15:30
Joint M.	Edoardo MIDENA	



14:00	4361	Choroidal tumor biopsy: a prospective case series KHURSHID G, COUPLAND S, DAMATO B–Liverpool
14:15	4362	Endoresection of choroidal melanoma after proton beam radiotherapy KHURSHID G, GROENWALD C, DAMATO B–Liverpool
14:30	4363	In vivo prognostication of posterior uveal melanoma: cost effectiveness and clinical value of different molecular tests PARROZZANI R, MIDENA E–Padova
14:45	4364	An European protocol for the detection and treatment of high risk uveal melanoma DESJARDINS L, COUTURIER J, PIPERNO-NEUMANN S–Paris
15:00	4365	Correlation between ultrasonographic tumor data and peritumoral subretinal fluid findings with OCT for the early detection of small malignant melanocytic tumors GRANGE JD, GARNIER S, JEAN-LOUIS B, ABI-AYAD N, KODJIKIAN L
15:15	4366	Validating the Helsinki University Central Hospital (HUCH) working formulation for staging metastatic uveal melanoma ESKELIN S, PIPERNO-NEUMANN S, DESJARDIN L, SCHMITTEL A, BECHRakis N, MIDENA E, GRANGE JD, RACT-MADOUX G, MARSHALL E, DAMATO B, LEYVRAZ S, ZOGRAFOS L, KIVELÄ T–Helsinki

### Poster session 3

15:35 – 16:25

### Europa C

Posters on pages 56-57

### Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History - Glaucoma - Physiology / Biochemistry / Pharmacology

Lene MARTIN, Tulin BERK - Gabor HOLLO, Michèle DETRY - Leopold SCHMETTERER, William STEWART

<b>Europa A</b>	<b>Corneal cross linking</b>		16:30 – 18:00
SIS	Theo SEILER, Rafael I. BARRAQUER		
16:30	4411	Corneal Cross Linking SEILER T–Zurich	
16:41	4412	Aspects of safety of riboflavin-UVA crosslinking of the cornea SPOERL E, MROCHEN M–Dresden, Zurich	
16:52	4413	Corneal molding and crosslinking BARRAQUER RI, LAMARCA J, SALVADOR B, ALVAREZ DE TOLEDO JP–Barcelona	
17:03	4414	Riboflavin/Ultraviolet a corneal collagen Cross-Linking: one-year results ROSETTA P, VINCIGUERRA P, ALBE E–Milano	
17:14	4415	Ocular response analyzer findings in keratoconic eyes undergoing Cross Linking procedure ALBE E, VINCIGUERRA PV, ROSETTA P–Milano	
17:25	4416	Crosslinking in iatrogenic keratectasia after LASIK: pregnancy-related exacerbation HAFEZI F, SEILER T–Zurich	
17:36	4417	Micromorphological analysis of cross-linked cornea by in vivo scanning laser MAZZOTTA C, CAPOROSSI A, BAIOCCHI S, CAPOROSSI O–Siena	
17:47	4418	Mid term results in keratoconus treatment by Riboflavin – UVA corneal collagen Cross-Linking. Siena eye cross project CAPOROSSI A, BAIOCCHI S, MAZZOTTA C, CAPOROSSI T–Siena, Rome	
<b>Europa B</b>	<b>Free Papers: Diabetic macular edema</b>		16:30 – 18:00
FP	Constantin POURNARAS, Frank VERBRAAK		
16:30	4421	Diabetic retinopathy screening with nonmydriatic fundus camera(1 and 3 fields) vs ETDRS standard MASSIGNAN F, VUJOSEVIC S, BENETTI E, PILOTTO E, MIDENA E–Padova, Roma	
16:42	4422	Diabetes related complications – the Moorfields Diabetes Survey PETO T, LEUNG I, HARRIS N, XING W, BUNCE C–London	
16:54	4423	Retinal fixation in Diabetic Macular Edema BOTTEGA E, VUJOSEVIC S, PILOTTO E, MIDENA E–Padova, Roma	
17:06	4424	Decreased OCT measured central retinal thickness in patients with and without minimal diabetic retinopathy KOK PHB, VAN DIJK HW, BIALLOSTERSKI C, VAN VELTHOVEN MEJ, VERBRAAK FD–Amsterdam	
17:18	4425	Difference in laser treatment decisions for diabetic macular edema, based on biomicroscopy or OCT VERBRAAK F, VAN DIJK H, KOK PHB, SCHLINGEMANN RO, ABRAMOFF M–Amsterdam, Iowa City	
17:30	4426	Two-year follow-up of patients with Diabetic Macular Edema (DME) treated with pegaptanib (Macugen) MEHRA S, MACUGEN DIABETIC RETINOPATHY STUDY GROUP–New York	
<b>Emerald I</b>	<b>Free Papers: Neuro-ophthalmology / Strabismology / Paediatric / History</b>		16:30 – 18:00
FP	Pinar AYDIN, Gordon PLANT		
16:30	4431	Correlation between saccadic parameter variations and clinical evidences in thyroid autoimmune ophthalmopathy (TAO) affected patients VARANO L, CAMPAGNA F, BRUZZICHESI D, CARNOVALE SCALZO G, PAOLA A, RUSSO C, SCORCIA V, PARISE S, ARTURI F, COSTANTE G, SCORCIA G–Catanzaro	
16:42	4432	Methods for quantifying diplopia HOLMES JM, HATT SR, LESKE DA, ADAMS WE–Rochester, MN	
16:54	4433	The development of psychiatric disease in young adults who had childhood strabismus MOHNEY BG–Rochester	
17:06	4434	Neural and behavioral mapping of the visual field in true and simulated visual field deficits KOZAK LR, SZATMARY G, VIDNYANSZKY Z–Budapest	
17:18	4435	A case of 2 brothers with congenital horner's syndrome PIERCE CO, SINCLAIR N, EVANS A–Cosham	
17:30	4436	Harry Moss Traquair (1875-1954) – Scottish ophthalmologist and perimetrist GRZYBOWSKI A–Poznań	

**Mediterranea I Free Papers: Optic nerve and sclera**

16:30 – 18:00

FP Neville OSBORNE, Selim ORGUL

16:30	4451	Ocular hemodynamic effects of nitrovasodilators in healthy subjects POLSKA E, KISS B, KOCH B, SCHMETTERER L–Vienna
16:42	4452	Optic nerve reflectivity variations during diffuse luminance flicker stimulation BONAIUTI M, ROVATI L, RIVA CE–Modena, Bologna
16:54	4453	Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, Survivin and Bcl-2 KERNT M, NEUBAUER AS, YU AL, KAMPIK A, WELGE-LUSSEN U–Munich
17:06	4454	Support for the idea that light is a risk factor in optic neuropathies, like glaucoma OSBORNE NN–Oxford
17:18	4455	Effect of induced myopia on scleral mechanics and myofibroblast populations BACKHOUSE S, BUMSTED O'BRIEN K, PHILLIPS JR–Auckland
17:30	4456	Topical beta-blockers and the risk of cardiovascular mortality JANSONIUS NM, WOLFS RCW, WITTEMAN JC, HOFMAN A, DE JONG PTVM, STRICKER BHC, MUSKENS RPHM–Groningen, Rotterdam, Amsterdam

**Adria OOG: Business meeting**

16:30 – 18:00

Joint M. Edoardo MIDENA

OOG

- Minutes of the last meeting: approval
- EVER-OOG relationship
- OOG sessions (during other meetings)
- OOG 2008 spring meeting
- New members
- Annual fee and financial report
- TBA

**General Assembly**

18:05 – 19:00


**Europa A****EVER General assembly and prize giving****Agenda**

1. President's address
2. Minutes of the General Assembly 2006
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, approval of the accounts 2006, discharge to the directors, budget for 2007
6. Newsletters ; EVER Journal
7. Results of the elections
8. Presentation of the BOARD 2007-2008
9. President Elect, Vice President Elect
10. Categories of membership
11. Presentation and report of the scientific sections meetings
12. Future congresses
13. Prize giving
14. Miscellanea

**Social**  
20-00-23:00  
in Laguna Bernardin

**EVER Farewell dinner**

with musical entertainment by Mia Znidaric (vocal) and Steve Klink (piano)



## Neuro-ophthalmology/Strabismology/ Paediatric ophthalmology / History

**Moderators:**  
**Lene MARTIN, Tulin BERK**

- 401 Optic radiation damage can be assessed directly by tractography  
YAMAMOTO T, YAMADA K, PLANT GT—Kumamoto, Kyoto, London
- 402 Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency in anterior ischemic optic neuropathy  
PINNA A, MASIA C, SOLINAS G, ZINELLI A, CARTA A—Sassari, Parma
- 403 Diagnosis and follow-up in patients with optic neuritis by means of optical coherence tomography (OCT) and scanning laser polarimetry (GDx)  
EGEA ESTOPINAN MC, PUEYO ROYO V, GUERRI N, SANCHEZ CANO A, FERNANDEZ TIRADO FJ, RABINAL ARBUES F, HONRUBIA FM—Zaragoza
- 404 Ocular motility disorders in a Fabry patient  
LANZL I, MAIER M, ZIMMERMANN P, HAEFFELE V, FIORE B—Munich
- 405 Visual function vs. spastic quadriplegia & brain damage  
KAPSOS A, KOZEIS N, BOSKOS G, MOSCHOU V, LAKE S—Thessaloniki
- 406 Visual functional assessment- Kozeis test:  
a new eye test for cerebral palsied children  
AGGELIDOU A, KOZEIS N, STOJANOVIC N, KAPSOS A—Thessaloniki
- 407 Could vision prognose cerebral palsy children's development ?  
TIGANITA S, KOZEIS N, KOKKINOU D, LAKE S, GEORGIADIS N—Thessaloniki
- 408 Visual function vs. spastic diplegia & brain damage  
GOGAKI EG, KOZEIS N, FELEKIDIS A, GEORGIADIS N—Thessaloniki
- 409 Peculiarities of pupil reactions in patients with hyperopic amblyopia in dependence of monocular fixation  
BUSHUYEVA NN, BOYCHUK IM, KHRAMENKO NI, SHAKIR DUHIRE MH—Odessa

## Glaucoma

**Moderators:**  
**Gabor HOLLO, Michèle DETRY**

- 410 Dynamic retinal vessel reaction in patients with primary open angle glaucoma  
*rf* SEIDOV A, KOTLIAR KE, VON DÜRING C, LANZL I—Munich, Passau
- 411 Abnormal peripheral vascular response to occlusion provocation in normal tension glaucoma patients  
*rf* WIERZBOWSKA J, STANKIEWICZ A, BURSA P, MANIEWSKI R, LIBERT A, ZBIEC A, WOJTKIEWICZ S, SIERDZINSKI J—Warsaw
- 412 Structure-function relationship in the process of primary open-angle glaucoma - an OCT study  
*rf* AJTONY CS, BALLA ZS, KOVACS B—Pécs
- 413 Glaucoma progression with GDx-VCC  
*rf* TOTH M, HOLLO G—Budapest
- 414 Outcome and risk factors for failure of primary trabeculectomy  
MEDVED N, CVENKEL B—Ljubljana
- 415 Treatment of patients with late complications after filtering surgery  
BEDNAR I, LACMANOVIC LONCAR V, KONJEVIC-PERNAR S, MANDIC Z—Zagreb
- 416 Ultrasound biomicroscopy in non penetrating filtration surgery with 5-Fluorouracil and without implant: long-term results  
GUTIERREZ C, VLEMING E, PAREJA J, BOLIVAR G, TEUS MA—Madrid
- 417 Trabeculectomy and Mitomycin C (Trab-MMC) for uveitic glaucoma: post surgical interventions  
LOCKWOOD A, SII F, CHIANG M, WILLIAMS TA, SHAH P—Birmingham
- 418 Long term outcome of bleb needling revisions following mitomycin C trabeculectomy in Afro-Caribbean eyes  
WILLIAMS TA, CROSBY N, SII F, CHIANG M, LOCKWOOD A, SHAH P—Birmingham
- 419 Intravitreal bevacizumab for neovascular glaucoma  
ANDRIJEVIC DERK B, MANDIC Z, BENCIC G, VATAVUK Z, NOVAK-LAUS K—Zagreb

- 420 Is nonadherence with eye drop treatment associated with increased intraocular pressure?  
VANDENBROECK S, DOBBELS F, DE GEEST S, STALMANS I, ZEYEN T—Leuven

- 421 Adjunctive use of tafluprost with timolol provides additive effects for reduction in intraocular pressure in patients with glaucoma  
EGOROV E, ROPO A—Moscow, Helsinki

- 422 The IOP-lowering efficacy of once-daily Travoprost /Timolol dosed in the morning compared to twice-daily Dorzolamide /Timolol for patients with open-angle glaucoma or ocular hypertension  
HOLLO G, LAGANOVSKA G, VOLKSONE L, TEUS MA—Budapest, Riga, Madrid

- 423 The influence of selective laser trabeculoplasty on diurnal intraocular pressure in POAG  
KOTHY P, TOTH M, HOLLO G—Budapest

- 424 Nycthemeral rhythm of intraocular pressure in normal tension glaucoma  
RENARD ER, PALOMBI KP, CHIQUET CC, PEPIN JLP, NOEL CN, ROMANET JPR—Grenoble

- 425 Ophthalmoscopic estimation of cup-to-disc ratio and its relation to the evening intraocular pressure in normal individuals  
CHATZIBALIST T, KARAMPATAKIS V, GKIKI M, BENOS A—Thessaloniki

- 426 Effectiveness of intraocular pressure phasing  
ARIF FARIS, HARDING A, HENSON D, SPENCER F—Hereford, Manchester

- 427 Short-term influence of antiglaucomatous medications on the ocular pulse amplitude (OPA) measured with the dynamic contour tonometer Pascal®  
DETTRY-MOREL M, JAMART J, POURJAVAN S—Brussels, Yvoir

- 428 The comparison of the quality score of IOP and ocular pulse amplitude (OPA) values measured by dynamic contour tonometer  
BOGOHSSIAN P, BERKOUK K, DETRY- MOREL M, POURJAVAN S—Brussels

- 429 Dynamic contour tonometry in corneal oedema  
RENNINGS CA, PLANGE N, KAUP M, REMKY A—Aachen

- 430 Comparison of DCT, GAT and ORA values in patients with glaucoma  
BREDOW L, LAUTEBACH S, HERDENER S, REINHARD T, PACHE M—Freiburg

- 431 Correlation between ocular response analyzer (ora) and dynamic contour tonometer (pdct) parameters in normal subjects and in glaucoma patients  
EHONGO A, DE MAERTELAER V, COLLIGNON N, POURJAVAN S—Brussels, Liège

- 432 Are pachymetric and tonometric asymmetry related?  
ALEMANY MARQUEZ P, JIMENEZ-CARMONA S, FAILDE I, CARRAL F, JORDANO J—Cadiç

- 433 Influence of diabetes on central corneal thickness in type II ocular hypertensive patients  
JIMENEZ-CARMONA S, ALEMANY MARQUEZ P, FAILDE I, CARRAL F, JORDANO J—Cadiç

- 434 Correlation between global indices of short-wavelength automated perimetry and GDx VCC parameters  
FERRERAS A, PAJARIN AB, LARROSA JM, POLO V, BORQUE E, HONRUBIA FM—Zaragoza

- 435 Diagnostic ability of GDx VCC to discriminate between healthy eyes, ocular hypertensive subjects and glaucoma patients  
BORQUE E, FERRERAS A, POLO V, LARROSA JM, ALIAS E, HONRUBIA FM—Zaragoza

- 436 Correlations between retinal nerve fiber layer measurements obtained with the GDx VCC and standard automated perimetry  
LOPEZ MJ, FERRERAS A, POLO V, LARROSA POVES JM, ALIAS ALEGRE EG, BORQUE RODRIGUEZ E—Zaragoza

- 437 Evaluation of clinical and HRT II quantitative parameters to detect suspect and early glaucoma patients  
SANCHEZ CANO A, GUERRI N, EGEA ESTOPINAN MC, PEREZ OLIVAN S, PABLO JULVEZ LE—Zaragoza

- 438 Visualisation of reverse pupillary block using AC-OCT in primary pigment dispersion syndrome  
LAEMMER R, MARDIN CY, JUENEMANN AGM—Erlangen

- 439 Diagnostic coincidence of the technologies of analysis of image HRT, OCT and GDx-VCC  
ALIAS EG, BORQUE E, LARROSA JM, POLO V, FERRERAS A, HONRUBIA FM—Zaragoza


- 440 Influence of optic disc size in retinal nerve fiber analysis by OCT : could a customizable circular algorithm help to solve the problem?  
RECHICHI M, SCORCIA V, SCORCIA GB, CARNOVALE SCALZO G, BRUZZICHESI D, SCORCIA G-Catanzaro
- 441 prevalence of exfoliation syndrome in Pella-Greece  
TSIRONI S, BENOS A, ZAFIRIADIS A, MICHAEL R, TSAOUSIS G, MIKROPOULOS D, KONSTAS AG-Thessaloniki, Edessa
- 442 The impact of clinical variables on the visual field damage of patients with pseudoexfoliative glaucoma  
MARTÍNEZ-GARCÍA A, SÁNCHEZ-SALORIO M-Santiago de Compostela
- 443 Superoxide dismutase, glutathione reductase and glutathione peroxidase activities in the whole blood of exfoliation syndrome and exfoliation glaucoma patients  
BLOMSTER HT, NURMI A, PUUSTJÄRVI T, KAIKKONEN J, KONTKANEN M, HILTUNEN R, TERÄSVIRTA M, SALONEN JT, VILPO T-Lahti, Helsinki, Kuopio, Joensuu
- 444 The prevalence of glaucoma and ocular hypertension in a population of Polish young men  
NOWAK MS, GOS R, KLYSIK AB, SMIĘGIELSKI J-Lodz
- 445 Elevated levels of 3-Nitrotyrosine (3-NT) in human eyes with primary open-angle glaucoma (POAG)  
FERNANDEZ-DURANGO R, FERNANDEZ-MARTINEZ A, GARCIA FEIJOO J, MARTINEZ DE LA CASA JM, FERNANDEZ-CRUZ A-Madrid
- 446 Characterization of a rat model of glaucoma induced by laser  
BRON AM, SCHNEBELEN C, SALINAS-NAVARRO M, ACAR N, PASQUIS B, CREUZOT-GARCHER C, VIDAL-SANZ M, BRETILLON L-Dijon, Murcia
- 447 Experimental glaucoma development in albino rabbits  
GUERRI N, EGEA ESTOPINAN MC, GARCIA MA, PEREZ-OLIVAN S, LOU JM-Zaragoza, Huesca
- 448 ATD perimetry in glaucoma and ocular hypertensive patients.  
A preliminar study  
MORILLA A, ANTON A, JMENEZ B, RODRIGUEZ C, MARTINEZ V, FALLON M, CAPILLA P, LUQUE MJ, FELIPE A, ARTIGAS JM-Barcelona, Valencia
- 449 FDT Matrix 24-2 threshold strategy for the evaluation of glaucoma suspects and ocular hypertensive eyes  
MICHELONE L, TROVARELLI S, MADONIA M, DA POZZO S, DI LAURO MT, SORCE G, RAVALICO G-Trieste
- 450 Epidemiology and follow-up of pigmentary glaucoma in Calabria  
MATTACE A, MANGIALAVORI D, SCANDALE M, PESCE GF, CARNOVALE SCALZO G, SETTINO G, SCORCIA V, SCORCIA GB, RECHICHI M, SCORCIA G-Catanzaro

## Physiology/Biochemistry/Pharmacology

**Moderators:**  
**Leopold SCHMETTERER, William STEWART**

- 451 Use of Travalert® in routine clinical practice  
STEWART WC, JASEK MC, STEWART JA-Forth Worth, Charleston
- 452 Local tolerability of Timolol 0,5% / Timolol 0,004% (DuoTrav ®) fixed combination in patients with open-angle glaucoma  
PESCE G, RECHICHI M, CATALANO C, SCORCIA V, CARNOVALE SCALZO G, SCORCIA G-Catanzaro
- 453 Pharmacokinetics of preserved and preservative-free formulations of tafluprost are comparable in healthy volunteers  
UUSITALO H, KAARNIRANTA K, ROPO A-Kuopio, Helsinki
- 454 Reduction in intraocular pressure is equivalent between preserved and preservative-free formulations of tafluprost  
HAMACHER T, AIRAKSINEN J, RICHTER U, ROPO A-Starnberg, Oulu, Regensburg, Helsinki
- 455 In vitro comparison of the oxidative and proapoptotic effects of preserved latanoprost, travoprost, bimatoprost and preservative-free tafluprost on conjunctival epithelial cells  
BRASNU E, BRIGNOLE-BAUDOUIN F, RIANCHO L, GUENOUN JM, WARNET JM, BAUDOUIN C-Paris

- 456 Short-term effect of topical brimonidine tartrate on intrastromal pressure. an animal study  
BOLIVAR G, TEUS MA, GUTIERREZ CGO, CASTEJON MA-Alcalá de Henares
- 457 Neuropeptide y protects retina neural cells from ecstasy-induced neurotoxicity  
AMBROSIO AF, ALVARO AR, MARTINS J, FERNANDES E, BASTOS ML, CARVALHO F, CAVADAS C-Coimbra, Porto
- 458 The suppression of early angiogenic markers by the antiangiogenic aptamer Macugen® is dose dependent  
BOURGHARDT PEEBO B, KOULIKOVSKA M, FAGERHOLM P-Linkoping
- 459 Comparison among bevacizumab, ranibizumab and pegaptanib on human umbilical vein endothelial cells viability, apoptosis and proliferation  
CARNEIRO A, FALCAO M, SOARES R, AZEVEDO I, FALCAO-REIS F-Porto
- 460 Histopathological findings after intravitreal injection of Linezolid  
ALCOCER YUSTE P, PERIS MARTINEZ C, AVINO-MARTINEZ J, VILA C-Valencia
- 461 Photodynamic therapy with Verteporfin combined with intravitreal injection of Bevacizumab for central serous chorioretinopathy  
MAIER M-Munich
- 462 Ocular and systemic distribution, and excretion of radioactivity following topical ocular administration of 14C-TG100801 to pigmented rabbits  
STRUBLE C, CHOINSKI R, MARTIN M-Madison, San Diego
- 463 Intravitreal treatment with Erythropoietin (EPO) preserves visual function following ocular ischemia in rats  
DERSCH RD, JEHLE TJ, MESCHEDE WM, DIMITRIU CD, BACH MB, LAGREZE WL-Freiburg
- 464 Relation of crystallin and ischemia/Reperfusion injury model of the rat retina  
YANG YUNSIK, JANG JEONGUN, BAHK SONGCHUL, KIM JAEDUCK, CHUNG HUNTAEG-Icksan
- 465 Methylprednisolone (MP) failed to protect retinal ganglion cells and visual function following ocular ischemia in rats  
DIMITRIU C, JEHLE T, MESCHEDE W, LASSECK J, BACH M, LAGREZE W-Freiburg
- 466 Effects of (-)-bicuculline and gamma-aminobutyric acid on the NiCl<sub>2</sub> mediated stimulation of the ERG b-wave amplitude from the isolated superfused vertebrate retina  
SCHNEIDER T, SIAPICH SA, BANAT M, HESCHELER J, LÜKE M, SCHNEIDER T-Köln, Tuebingen
- 467 Arabinogalactan: a new ophthalmic vehicle for dry eye protection and treatment of corneal lesions  
BURGALASSI S, NICOSIA N, MONTI D, FALCONE G, BOLDRINI E, CHETONI P-Pisa, PISA, Corlo Di Formigine
- 468 Ocular surface retention time and extensions of TFBUT of a lubricating eye drop  
IPINAZAR UNDURRAGA M, OUSLER III GW, SCHINDELAR MR, PAUGH J-Barcelona, North Andover (MA), Fullerton (CA)
- 469 Nicardipine inhibits human conjunctival fibroblastic proliferation, migration and attachment in vitro  
GONZALVO IBANEZ F, FUERTES FERNANDEZ I, IZAGUIRRE RONCAL L, PINILLA LOZANO I-Estella, Pamplona, Zaragoza
- 470 Comparative study of commercially available antihistaminic drops in an animal model of early phase allergic conjunctivitis  
MONTERO-MORENO JA, SANCHIS-MERINO ME, RUIZ-MORENO JM, LUGO F, AMAT-PERAL P, DE LA VEGA C-Alicante, Valladolid
- 471 Frozen fortified antibiotic in ophthalmic solutions stability during 2 months  
MOURIAUX F, FINES-GUYON M, CHEREL A, PERDRIEL A, ALBESSARD A, DEBRUYNE D, CHEDRU-LEGROS V-Caen
- 472 The pentadapeptide BPC 157 antagonizes the effect of atropine effect in the rats` eyes  
MASNÉC-PASKALIN S, IVEKOVIC R, RADIC B, KLICEK R, BRCIC L, SEIWERTH S, SIKIRIC P, MANDIC Z-Zagreb
- 473 Characterization of COX-1 and -2 inhibition by nepafenac and its metabolite, amfenac  
KULMACZ RJ, GRAFF G-Houston, Fort Worth



# EVA 2007

## European Vision Award

by the European Vision Institute EEIG // [www.europeanvisioninstitute.org](http://www.europeanvisioninstitute.org)

The winner of the inaugural European Vision Award will be announced in a private reception during the EVER 2007 Congress on **Friday, October 5, 2007, 18:30 h** and again, open for the EVER public, on **Saturday, October 6, 2007, 10:55 h** after Professor Eberhart Zrenner's keynote lecture. The ceremony takes place in room EUROPA A.

The European Vision Institute's mission is to support programs and projects that develop, integrate and conduct vision research to prevent and treat eye diseases as well as to develop new therapeutic strategies to improve the quality of life for those suffering.

**[www.europeanvisioninstitute.org](http://www.europeanvisioninstitute.org)**

the EVA 2007 is supported by




## EVA 2008

### European Vision Award

Information about the 2008 European Vision Award and application is available on the website.

The European Vision Institute is currently accepting applications for membership. Please visit the website for more information.



ARVO  
2008  
ANNUAL  
MEETING

Eyes on  
innovation

■ APRIL 27-MAY 1, 2008 ■  
FORT LAUDERDALE, FLORIDA

## INDEX – PRESENTING FIRST AUTHORS

### KEYNOTE LECTURES

EHLERS, N: Wednesday, 17:20  
 DE LAEY, JJ: Wednesday, 18:05  
 KIVELÄ, T: Wednesday, 18:25  
 RAO, G: Thursday, 10:15  
 la COUR, M: Thursday, 15:45  
 JAGER, MJ: Friday, 10:15  
 HOLZ, F: Friday, 15:45  
 ZRENNER, E: Saturday, 10:15

ABU EL ASRAR A: 1356  
 AGERVI PH: 267  
 AGGELIDOU A: 406  
 AJTONY CS: 412, 4136  
 AKHTAR S: 206, 2356  
 ALBE E: 4415  
 ALCOCER-YUSTE P: 460  
 ALEMANY MARQUEZ P: 432  
 ALIAS EG: 439  
 ALTAN-YAYCIOGLU R: 246, 3162, 3364  
 ALYAHYA GA: 2364  
 AMBROSIO AF: 457  
 ANDRIJEVIC DERK B: 419  
 ARAKELYAN MA: 263  
 ARIF FARIS: 426  
 ARING E: 1332  
 ARNDT CF: 331, 3125  
 ASOKLIS R: 3412  
 ASPINAL PA: 4146  
 ASRANI S: 3232  
 AUDO I: 4123  
 BACKHÖUSE S: 4455  
 BARBAZZETTO IA: 3163  
 BÁRRAQUER J: 4211  
 BARRAQUER RI: 4413  
 BATAILLE L: 237, 3213  
 BEDNAR I: 415  
 BEKT T: 2231  
 BELIN MW: 4312  
 BELTRAM M: 247, 249  
 BERKT T: 1334  
 BERNARDES R: 3422  
 BLOMSTER HT: 443  
 BOCK FB: 2213  
 BODAGHI B: 233, 1353, 2117, 2216,  
     3151  
 BOGOHSSIAN P: 428  
 BOLIVAR G: 456  
 BONAIUTI M: 4452  
 BONSHEK RE: 351, 3462  
 BORQUE E: 435  
 BORRUAT FX: 4332  
 BOSCHI A: 4334  
 BOSKOS G: 365  
 BOTTEGA E: 4423  
 BOURCIER T: 1321, 2111  
 BOURGHARDT PEEBO B: 458  
 BOYCHUK IM: 361  
 BRASNU E: 455  
 BRAUTASET R: 1333  
 BRAVETTI GO: 312  
 BREDDOW L: 430  
 BRISCOE D: 3467

BRON AJ: 2311  
 BRON AM: 446, 3434  
 BRUENECH JR: 2252  
 BUCHT C: 3414  
 BURGALASSI S: 467  
 BUSHUYEVA NN: 409  
 BUSIN M: 4112  
 CAMELO S: 3153  
 CANADAS SUAREZ P: 227, 3312  
 CAPOROSI A: 4418  
 CARASSA RG: 2132  
 CARNEIRO A: 459  
 CARNOVALE SCALZO G: 332  
 CASANOVA C: 2241  
 CATALANO C: 363  
 CELLINI M: 329  
 CEZAYIRLI E: 2334  
 CHATEAU N: 4342  
 CHATZIBALIS T: 204, 425, 2458  
 CHE S: 307  
 COCHEREAU IC: 1354  
 COLBY K: 4311  
 COLLIGNON N: 3233  
 CORDEIRO MF: 3332  
 COUPLAND S: 4168, 4169  
 CRAWFORD G: 4313  
 DALKE C: 2422  
 DAMATO B: 4166  
 DAYANIR V: 3133  
 DEAK G: 2454  
 DE BELVIS V: 4163  
 DEB-JOARDAR N: 218  
 DE FRUTOS-BARAJA JM: 319  
 DE KEIZER RJW: 328, 3361  
 DELAMERE NA: 3241  
 DE LA PAZ MF: 2412  
 DEN BOER J: 3254  
 DERSCH R: 463  
 DESJARDINS L: 2365, 3263, 4364  
 DE SMEDT S: 2161  
 DE SMET M: 1355, 2115, 3152, 4145  
 DE SOUZA RAMALHO P: 3356  
 DETRY-MOREL M: 427  
 DIMITRIU C: 465  
 DODI PL: 213  
 DONG X: 303  
 DORE S: 367  
 D'SOUZA Y: 352, 4222  
 DUA HS: 1311, 1313, 3114, 4111  
 DUCASSE A: 2344  
 ECKER B: 2155  
 EGEA ESTOPINAN MC: 403  
 EGOROV E: 421  
 EHONGO A: 431  
 EICHHORN M: 4352  
 EL MATRI L: 353  
 ELOY P: 2342, 2345  
 ESKELIN S: 4366  
 EVCIMAN T: 315  
 FAGERHOLM P: 4315  
 FAINGOLD D: 320  
 FALCAO M: 4226  
 FARKAS A: 254  
 FERAILLE L: 3274

FERNANDES BF: 321, 3363  
 FERNANDEZ-DURANGO R: 445  
 FERRERAS A: 434  
 FRANCIS I: 4213  
 FRESINA M: 212  
 FRUCHT-PERY J: 3261, 3265  
 FUCHSJAEGER-MAYRL G: 4231  
 GALICHANIN K: 304  
 GALLAGHER MJ: 3325  
 GANDOLFI S: 3334  
 GARCHER CREUZOT C: 259, 370  
 GARCIA-ALVAREZ C: 318, 3366  
 GARCIA CAMPOS JM: 339  
 GARDEA E: 223  
 GARHOFER G: 3453  
 GARWEG JG: 2112  
 GEORGIAUDOU I: 2131  
 GICQUEL JJ: 311, 1315, 1323, 2413, 4343  
 GIPSON IK: 2316  
 GLOBOCNIK PETROVIC M: 347, 2124  
 GOGAKI EG: 408  
 GONZALVO IBANEZ F: 469  
 GRABNER G: 4144  
 GRAHAM JE: 236  
 GRANGE JD: 4365  
 GRAW J: 2121  
 GRZYBOWSKI A: 4436  
 GUERRI N: 447  
 GUGGENHEIM JA: 2225  
 GUNGOR K: 2331  
 GUTHOFF RF: 3113, 4261  
 GUTIERREZ C: 416  
 HADJISTILIANOU T: 324, 2366  
 HAFEZI F: 4416  
 HAMACHER T: 454  
 HAMEDANI M: 3464  
 HAMMAR B: 2426  
 HARDARSON SH: 2233, 3456  
 HARJU M: 4133  
 HASHIMOTO T: 257  
 HAUGEN IBK: 2253  
 HAWLINA M: 2141, 2424, 2435, 4152  
 HAYASHI T: 2243  
 HEEGAARD S: 4264  
 HEIREMAN S: 2162  
 HEJSEK L: 3323  
 HENC-PETRINOVIC LJ: 3365  
 HERBORT C: 2113  
 HERDENER S: 230  
 HILLARBY MC: 256  
 HOLDER GE: 2144, 3224, 4154, 4263  
 HOLLO G: 422, 2134, 4132  
 HOLMES JM: 4432  
 HOPKINSON A: 1314  
 HORWITZ J: 3246  
 HUANG S: 305  
 HUNTER A: 3424  
 IBANEZ J: 342  
 IOMDINA EN: 369  
 IPINAZAR UNDURRAGA M: 468  
 IRION LD: 3367  
 JANSONIUS NM: 4456  
 JANSSENS S: 3354

JARC-VIDMAR M: 255  
 JAVDANI Z: 2341, 2443, 2444  
 JEHLE T: 264  
 JIMENEZ-CARMONA S: 433  
 JING W: 3352  
 JIRSOVA K: 2354  
 JONAS JB: 337, 3433, 4245  
 JONASSON F: 4221, 4244  
 JUDICE DE MENEZES RELVAS L: 209  
 JUKLOVA K: 226  
 KAARNIRANTA K: 4323  
 KAIMBO WA KAIMBO D: 250  
 KALMAN R: 314  
 KANG CY: 316  
 KAPSOS A: 405  
 KARLSSON JO: 3351  
 KAWASAKI A: 4331  
 KAZARYAN AA: 270  
 KERNT M: 4453  
 KESTELYN P: 4114  
 KHURSHID G: 4361, 4362  
 KIVELÄ T: 2361  
 KNEZEVIC T: 323  
 KNOP E: 2462  
 KNOP N: 2151, 2465  
 KODJIKIAN L: 1322, 1351, 2116  
 KOJIMA M: 2355  
 KOK PHB: 4424  
 KONSTAS AGP: 3134, 3234  
 KOPITZ J: 4322  
 KOTHY P: 423  
 KOTLIAR KE: 317, 3124  
 KOUBA M: 2154  
 KOULIKOVSKA M: 205  
 KOUPRIANOFF S: 239  
 KOZAK LR: 4434  
 KRAAK R: 2464  
 KRUSE FE: 3272  
 KULKARNI B: 2353  
 KULMACZ RJ: 473  
 KURVINEN L: 4233  
 LABBE A: 2467  
 LACHAPELLE P: 2242  
 LACHMUND U: 2343  
 LAEMMER R: 438, 4135  
 LAITINEN A: 252  
 LAMAR PD: 4314  
 LAMBERT V: 4353  
 LANGMAN ME: 242, 3215, 4341  
 LANZL IM: 404, 3454  
 LARA MEDINA J: 360  
 LAZUK AV: 341  
 LEATHERBARROW B: 3461  
 LEIVO T: 3344  
 LELOUP E: 2163  
 LEMP MA: 2315  
 LENGYEL I: 202, 2456  
 LEROY BP: 2143, 3221  
 LEYS A: 3322  
 LIBONDI T: 253, 2122  
 LIESENFELD O: 2114  
 LIEW G: 2221  
 LIINAMAA MJ: 344  
 LINDBOHM NM: 3311

## INDEX – PRESENTING FIRST AUTHORS

- LINDSKOOG PETTERSSON A: 214  
 LIU C: 3341  
 LOCKWOOD A: 417  
 LOEFFLER K: 4161, 4162  
 LOPEZ MJ: 436  
 LOPEZ-GIL N: 4344  
 LOU MF: 3441  
 LÜKE C: 357  
 MACKENSEN F: 2215  
 MADIGAN MC: 3362  
 MAHARAJAN S: 1312  
 MAIER M: 461  
 MALANDRINI A: 216  
 MANNERMAA E: 3355  
 MANTEL I: 2123  
 MARTIN L: 306, 1331, 2245  
 MARTÍNEZ-GARCÍA A: 442  
 MASNEC-PASKVALIN S: 472  
 MASSIGNAN F: 4421  
 MATTACE A: 450  
 MAVRIKAKIS I: 2346  
 MAZZOTTA C: 4417  
 MCAVOY JW: 3245  
 MCGILLIGAN V: 232  
 MCLOON L: 2251  
 MEDVED N: 414  
 MEHRA S: 4426  
 MELLES GRJ: 4113  
 MELONI M: 3273  
 MENCHINI F: 4122  
 MENEZO ROZALEN JL: 310  
 MERGLER S: 222  
 MERJAVA S: 221  
 MEYER L: 3445  
 MICHAEL R: 2414, 4143  
 MICHELONE L: 330, 449, 3126  
 MIDENA E: 3164  
 MIKEK K: 2411  
 MILANO G: 4131  
 MILEA D: 4262, 4333  
 MISSOTTEN GS: 326, 2164, 2363  
 MISSOTTEN T: 3324  
 MODY V: 301  
 MOESSNER A: 348  
 MOHNEY BG: 4433  
 MOJON D: 1341  
 MOJON - AZZI S: 1342  
 MONTAN P: 1352  
 MONTERO-MORENO JA: 470  
 MOORE JE: 235, 3212  
 MOORE T: 2142, 3222  
 MORILLA A: 448  
 MOURIAUX F: 471, 3466  
 MURAINÉ M: 210, 3415  
 NEJEPINSKA J: 224  
 NEPP J: 2152  
 NGUYEN KHOA JL: 4345  
 NILSSON M: 260, 265, 2246  
 NOURI M: 4316  
 NOVAK ANDREJCIC K: 4165  
 NOWAK MS: 269, 444  
 NUBILE M: 2466, 3111  
 NUUTS RMMA: 4115  
 O'TOOLE L: 4121  
 OBROSOVA IG: 2452  
 OLOFSSON EM: 3443  
 ORZALESI N: 3235  
 OSBORNE NN: 4454  
 OWENS H: 3314  
 OZKURT Y: 343  
 PARISE S: 356  
 PARROZZANI R: 2362, 4363  
 PASCAL HASLER: 335  
 PATEL SV: 229  
 PATTERI P: 243  
 PATTON WP: 349  
 PEDROSA DOMELLO F: 2255  
 PE'ER J: 3262, 3264, 4167  
 PEETERS L: 2261  
 PEMP B: 3451  
 PERERA S: 4212  
 PERIS MARTINEZ C: 309, 3411  
 PEROVSEK D: 203, 2457  
 PESCE G: 452  
 PETERSEN A: 3442  
 PETO T: 350, 4422  
 PHILLIPS JR: 2244  
 PIERCE CO: 358, 4435  
 PINELLO L: 244, 2126  
 PINNA A: 402  
 PISELLA PJ: 3271  
 PLANGE N: 4235  
 PLEYER U: 2434, 3156, 3413  
 PODSKOCHY A: 215  
 POLSKA E: 4451  
 POPOVIC P: 336  
 POPPER M: 2125  
 POURJAVAN S: 3431  
 POURNARAS CJ: 364, 2232  
 PRAUSE JU: 4265  
 PUECH C: 240  
 PUK O: 2421  
 RADIN PP: 4164  
 RECHICHI M: 440  
 REGINALD AY: 3316  
 REHAK M: 366  
 REITSAMER HAR: 3455  
 REMKY A: 4234  
 RENARD E: 424  
 RENNINGS CA: 429  
 REQUEJO-ISIDRO J: 3251  
 RICHTER MÜKSCH S: 2153  
 ROBIN A: 2135  
 ROCHA DE SOUSA A: 207, 3353  
 RODRIGUEZ AE: 231, 3315  
 ROLDAN-PALLARES M: 3123  
 ROMANET JP: 3231  
 ROSETTA P: 4414  
 ROSNER M: 3161  
 ROVATI L: 3255  
 RUBERTO G: 4153  
 RUGGERI A: 2417, 3423  
 RUIZ MORENO JM: 355  
 RYDZANICZ MA: 258  
 RYHÄNEN T: 208  
 SAHEL JA: 3223  
 SANCHEZ CANO A: 437  
 SANCHEZ CHICHARRO DI: 345, 3127  
 SANDERSON J: 3242  
 SANTOS T: 3121  
 SARKADY E: 322  
 SASAKI H: 4246  
 SASAKI K: 4243  
 SAW SM: 2224  
 SCHAUMBERG D: 2314  
 SCHLOETZER SCHREHARDT U: 3132, 4354  
 SCHMETTERER L: 4232  
 SCHNEIDER T: 466  
 SCHWARTZ A: 3421  
 SEDOVA SF: 241, 410, 4236  
 SEILER T: 4411  
 SEppo M: 4324  
 SEREGARD S: 2433  
 SERRA F: 2446  
 SHAMSHINOVA AM: 268, 271  
 SHANG F: 3444  
 SKET KONTESTABILE A: 325  
 SKINNER KC: 217  
 SKORKOVSKA SS: 4134  
 SKUNCA J: 313  
 SLEATH B: 2133  
 SMITH G: 3342  
 SMITH JA: 2312  
 SÖDERBERG PG: 4241  
 SOMFAI GM: 346  
 SPIELEERS W: 2432  
 SPOERL E: 4412  
 STACHS O: 2461  
 STALMANS I: 3452  
 STEFANSSON E: 2234  
 STEWART EA: 4225  
 STEWART WC: 451  
 STIRN KRANJC B: 2445  
 STOJANOVIC N: 251  
 STRUBLE C: 462  
 STUNF S: 308  
 SUOMINEN S: 3435  
 SYNEK S: 338  
 TARUTA EP: 362  
 TASSIGNON MJ: 2431, 4142  
 TATRAI E: 333  
 TERRADA C: 3154  
 TEUS MA: 225, 3135, 3313  
 THIADENS AAHJ: 262  
 THURET G: 2416  
 TIFFANY JM: 3211  
 TIGANITA S: 407  
 TOMLINSON A: 2313  
 TOSOUNIDIS IH: 245, 327, 2127  
 TOTH M: 413, 4137  
 TOUITOU V: 2212, 3155  
 TSANG SH: 4126  
 TSIRONI S: 441, 2136, 3131  
 TUGLU I: 2332  
 TUNC M: 3463  
 UNGERECHTS R: 2442  
 UNTERHUBER A: 3253  
 URBANCIC M: 368  
 UUSITALO H: 453  
 VACLAVIK V: 4124  
 VALENZUELA EG: 2333  
 VA'MOS R: 359  
 VAN BERGEN T: 2262  
 VAN DEN BERG TJTP: 261, 4141  
 VANDENBROECK S: 420  
 VAN DER WERF F: 2254  
 VAN DE VEIRE S: 2263, 3321  
 VANDEWALLE E: 3432  
 VAN DIJK HW: 340  
 VAN GINDERDEUREN R: 2453  
 VARANO L: 354, 4431  
 VARSANYI B: 334  
 VATAVUK Z: 2425  
 VELLONEN KS: 201, 2357  
 VERBRAAK FD: 4425  
 VERSURA P: 220, 3216  
 VIDOVIC VALENTINCIC N: 234, 2217  
 VINCIGUERRA P: 3112  
 VINH V: 238, 2211  
 VISWANATHAN A: 3333  
 VITHANI EN: 2222  
 VOSSMERBAEUMER U: 211, 3416  
 VUJOSEVIC S: 4125  
 WAHLBERG M: 266  
 WANG J: 3446  
 WANG L: 3243  
 WEGENER AR: 4242  
 WEIGERT G: 4223  
 WELGE-LUSSEN U: 2451, 4321  
 WHEELER LA: 3331  
 WHITE JES: 3343  
 WIERZBOWSKA J: 411, 4237  
 WILHELM K: 2441  
 WILKE M: 248  
 WILKE R: 2423  
 WILLERMAIN F: 2214  
 WILLIAMS TA: 418  
 WILSHAW H: 3465  
 WIROSTKO B: 3326  
 WOLZT M: 4351  
 WONG D: 4214, 4215  
 WOOD TO: 3214  
 WORMSTONE IM: 3244  
 YAMAMOTO T: 401  
 YANG YUNSIK: 464  
 YAP E: 2223  
 YASUNO Y: 3252  
 YEUNG AM: 2352  
 YU AL: 2455  
 ZAKARIA N: 2264  
 ZEYEN T: 3436  
 ZHANG Y: 302  
 ZHAO M: 219  
 ZHIVOV A: 2463  
 ZOGRAFOS L: 3122  
 ZOLNIKOVA IV: 4224  
 ZRENNER E: 4151

This programme book is organised chronologically

Four digit numbers refer to oral presentations

Three digit numbers refer to posters

X X X  
Day | Order in the postersession

The sessions are colour-coded

## Special Interest Symposium (SIS)

## Free Papers

## Joint Meeting

Keynote Lecture

General Assembly & Business Meeting

Course

Commercial Interest Symposium

Workshop

## Poster Session

Social

FP = Free Paper session

## **SIS = Special Interest Symposium**

**CIS** = Commercial Interest Symposium

*rf* = Rapid Fire presentation

 = Travel grant recipient

## **Scientific sections**

ACB	=	Anatomy/Cell Biology
COS	=	Cornea/Ocular Surface
G	=	Glaucoma
IM	=	Immunology/Microbiology
LC	=	Lens and Cataract
MBGE	=	Molecular Biology/Genetics/ Epidemiology
NSPH	=	Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/History of Ophthalmology
PBP	=	Physiology/Biochemistry/Pharmacology
PO	=	Pathology/Oncology
RV	=	Retina/Vitreous
VEP	=	Vision Sciences/Electrophysiol./Physiol. Opt.

## THANK YOU SPONSORS

This year EVER celebrates its 10<sup>th</sup> anniversary and would like to take the opportunity to thank all companies for their support during the first decennium.

Due to this support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER wishes everyone of its past and present sponsors good future for the comming years and thanks especially the following companies, many of which are our long-term supporters, for their generous sponsorship to the 10<sup>th</sup> congress

MAIN

**Alcon®**

MAJOR

 **Pfizer Ophthalmics**

 **Santen**

SIS

**Alcon®**

 **ALLERGAN**

 **MSD**

 **Pfizer Ophthalmics**

 **Santen**

 **ZEISS**

EXHIBITORS

 **IMEDOS**

 **Pfizer Ophthalmics**

 **ROLAND  
INSTRUMENTS**  
Electrophysiological diagnostic systems

 **ARVO**

CIS

 **Théa**

EVER 2007	Europa A	Europa B	Emerald I	Emerald II	Mediterranea I	Adria
WEDNESDAY , Oct. 3, 2007	Course 1: Amniotic HS DUA, JJ GICQUEL	Course 2: Corneal JJ GICQUEL, T BOURCIER	Course 3: Pediatric L MARTIN, P AYDIN	Course 4: Statistics D MOJON, S MOJON-AZZI	Course 5: Endophthalmitis MD DE SMET, L KODIKIAN	Course 6: Pathology S COUPLAND, K LOEFFLER
			Course 7: EBO exam Course — Bahram BODAGHI — Room Daphnia			
	Welcome by the President EVER 2007 - Uwe PLEYER					Europa A
	AER Lecture: On considerations of the corneal thickness - Niels EHLLERS					Europa A
	European Ophthalmologic Heritage - Jean-Jacques DE LAEY					Europa A
	EVER Lecture: Can uveal melanoma be conquered ? - Tero KIVELÄ					Europa A
	Opening concert — Zoran Predin, acoustic guitar - Anja Bukovec, violin - Zoran Skrinjar, piano					Europa A
	EVER Welcome reception					on St. Bernardin terrace
THURSDAY, Oct. 4, 2007	IM: Ocular zoonosis and uveitis L KODIKIAN, MD DE SMET	MBGE - FP: Epidemiology and genetics J GUGGENHEIM, T LIBONDI	G: Adherence with medical therapy A G.P. KONSTAS	VEP: Doctor, I don't like bright lights G HOLDER, Bart LEROY	ACB: Psycho - neuro - immunology and the eye J NEPP, N KNOP, E KNOP	FRO: Belgian Fund for Research in Ophthalmology 1 - MJ TASSIGNON
	Keynote Lecture 1: Delivery of eye care in developing countries - Role of research — Gullapalli RAO					
	IM - FP: Immunology / Microbiology CP HERBORT, U PLEYER	MBGE: Genetics of non-mendelian complex eye diseases - SM SAW, E YAP	EURETINA: How does the laser work? The mechanism of retinal photocoagulation - E STEFANSSON	VEP - FP: Vision Sciences / Electrophysiol. / Physiol. Optic - G HOLDER, B LEROY	ACB: Ocular movements: structural, functional & clinical aspects - F PEDROSA DOMELLOF, R BRUENECH	FRO: Belgian Fund for Research in Ophthalmology 2 - MJ TASSIGNON
FRIDAY, Oct 5, 2007						LUNCHTIME
	COS: A Report from the International Dry Eye Workshop - DA SCHAUERBERG, DA SULLIVAN	ARVO session: Mentoring: How, what, why & when S ATHERTON, N DELAMERE, T LIBONDI	G: Glaucomatous optic neuropathy K GUNGOR	The nasolacrimal duct, Part 1 Z JAVDANI	ACB - FP: Anatomy/Cell Biology 1 E KNOP, S AKHTAR	PO - FP: Oncology / Pathology 1 L DESJARDINS, E MIDENA
	Acta Lecture: The retinal pigment epithelium, friend or foe? - Morten la COUR					
	Poster session 1 : Anatomy/Cell Biology - Cornea/Ocular Surface - Immunology/Microbiology - Molecular Biology/Genetics/Epidemiology - Vision Sciences/Electrophysiol./Physiol. Optic					
SATURDAY, Oct 6, 2007	COS - FP: Keratoconus and corneal grafting G THURET, P KESTELYN	MBGE - FP: Genetics and animal models M HAWLINA, J GUGGENHEIM	CONCORDIA: Promoting European Education in Ophthalmology T KIVELÄ, S SEREGARD	The nasolacrimal duct, Part 2 Z JAVDANI	ACB - FP: Anatomy/Cell Biology 2 H UUSITALO, R BRUENECH	ACB: In vivo micro-anatomy of the ocular anterior segment by confocal laser scanning microscopy E KNOP, N KNOP, O STACHS, R GUTHOFF